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ABSTRACT 
 
 The MLL gene encodes a multi-domain protein that is involved in the 
maintenance of Hox gene expression during development and hematopoiesis, and was 
first identified through its involvement in chromosome translocations that cause 
leukemia. The CXXC domain of MLL, which is retained in leukemic MLL fusion 
proteins, is a cysteine rich DNA binding domain, with specificity for binding 
nonmethylated CpG-containing DNA, and is essential for MLL fusion proteins’ 
oncogenic properties.  
 Point mutations within MLL’s CXXC domain, at amino acids identified in 
structural and binding studies to be important for binding to target DNA, were introduced 
into the oncogenic MLL-AF9 fusion protein.  We performed domain swap experiments in 
which CpG binding domains from other proteins were swapped in to replace MLL’s 
CXXC domain in the context of an oncogenic MLL fusion.  CXXC domains from DNA 
methyltransferase 1 (DNMT1), CpG binding protein (CGBP), and methyl-CpG binding 
domain protein 1 (MBD1), as well as a methyl binding domain (MBD) from MBD1 were 
swapped into the MLL-AF9 fusion.  These particular domains were chosen because their 
described CpG DNA binding capacity is either similar or different from that described for 
MLL.  In vitro colony assays on isolated murine bone marrow progenitor cells infected 
with mutant or wild type MLL-AF9 fusion proteins were performed in order to determine 
whether CXXC point mutations or the CXXC domain swaps would affect the ability of 
 xiii 
MLL-AF9 to give an enhanced proliferative capacity to bone marrow progenitor cells. In 
vivo murine studies determined whether the CXXC mutations alter the ability of MLL 
fusion proteins to cause leukemia. We predicted that the point mutations and different 
CpG binding domains would change the strength or specificity of MLL binding to DNA, 
which would affect the ability of MLL-AF9 to cause leukemia.  
 In vitro DNA binding experiments were performed to directly measure and 
compare the DNA binding affinity of the isolated CXXC domain from MLL to the other 
domain swap proteins.  The results indicate that MLL CXXC domain has the highest 
binding affinity of the domains tested to the unmethylated DNA target.  CGBP CXXC 
domain has the second highest affinity, at about 7-fold lower than MLL CXXC.  DNMT 
CXXC could bind to this unmethylated DNA, but with a much lower affinity.  As 
expected, neither MBD1 CXXC nor MBD1 MBD was able to bind to the unmethylated 
DNA.   
 The results of both in vitro replating assays and in vivo leukemogenesis 
experiments have shown significant differences between the ability of various CpG DNA 
binding domains to function in the context of an MLL-AF9 fusion protein. The point 
mutations that showed reduced DNA binding also show reduced colony formation and a 
loss of ability to cause leukemia in mice when present in MLL-AF9.  MLL-AF9 
containing the DNMT1 CXXC domain shows robust in vitro colony forming activity and 
in vivo leukemogenesis activity, similar to the oncogenic MLL-AF9 fusion. However, 
MLL-AF9 containing either the CXXC domain from CGBP or MBD1, or the MBD 
domain of MBD1 all show reduced colony forming ability and leukemogenicity in vivo.  
 xiv 
This suggests that CXXC domain properties in addition to DNA binding affinity, perhaps 
including protein recruitment, also contribute to an MLL fusion protein’s leukemogenic 
properties.  
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CHAPTER 1 
 
INTRODUCTION 
 
 Leukemia involving the MLL (Mixed Lineage Leukemia) gene is a particularly 
aggressive disease that is correlated with a poor patient prognosis.1  MLL leukemia 
accounts for greater than eighty percent of infant leukemia, as well as up to 10% of adult 
leukemia.2  MLL leukemia develops when DNA damage occurs in a blood, or 
hematopoietic, stem or progenitor cell, so that the chromosome on which the MLL gene 
resides becomes broken and fused to a different chromosome.3  This translocation results 
in the fusion of two genes that encode a chimeric protein that is comprised of part of the 
MLL protein and part of another partner protein.  There have been more than sixty MLL 
fusion partners identified that result in either an acute myeloid, acute lymphoid, or a 
mixed lineage type of leukemia for which the MLL gene is named.4  My project utilizes 
the MLL-AF9 fusion protein, which is one of the more common MLL fusions observed 
in MLL leukemia patients.5  Understanding the molecular basis of how and why these 
MLL fusion proteins cause leukemia to develop is essential to developing an effective 
targeted therapy for the disease.  
 Proteins are divided into specific domains, based on their molecular structure and 
function.  This project focuses on a protein domain that is present in MLL and is retained 
in MLL fusion proteins, called the CXXC domain, which binds to DNA.  The MLL 
protein is known to interact with DNA at the promoters of specific genes and help to
2 
 
regulate the activity of these genes.6  When a leukemic MLL fusion protein is present in a 
cell, the normal target genes of MLL become misregulated by the MLL fusion protein.7  
When certain target genes of MLL, including HOXA9, become overactive, the normal 
process of blood cell development is disrupted, and leukemia develops.  The presence of 
the MLL CXXC domain has been shown to be essential for MLL fusion proteins to 
promote overexpression of target gene Hoxa9 and to transform bone marrow cells in 
vitro.8 
 The MLL CXXC domain is known to interact specifically with unmethylated DNA.8-
10  DNA methylation is an epigenetic modification that appears on certain CpG DNA 
motifs throughout the genome, and is associated with repression of gene transcription.11  
Unmethylated CpG DNA, on the other hand, is associated with active gene transcription 
when it is found in the promoters of certain genes.12  Our lab has previously shown that 
MLL and MLL fusion proteins bind to the Hoxa9 gene locus, and protect specific CpG 
motifs in this locus from becoming DNA methylated.  The MLL dependent DNA 
methylation status of these CpGs also correlates with Hoxa9 gene expression.6  We 
hypothesized that this DNA methylation protection function of MLL is facilitated by the 
MLL CXXC domain, as it is known to bind specifically to unmethylated DNA. 
 This project explores the functional role of the MLL CXXC domain in contributing to 
MLL leukemogenesis.  Our collaborators at John Bushweller’s laboratory at the 
University of Virginia recently solved the structure of the MLL CXXC domain in 
complex with unmethylated CpG DNA.  From this solved structure, they were able to 
identify the specific amino acids in the MLL CXXC domain that are involved in 
3 
contacting target CpG DNA.  The Bushweller laboratory designed amino acid point 
mutations that reduce or abolish the DNA binding affinity of the MLL CXXC domain, 
while keeping the structure of the domain intact.  In the first aim of my dissertation, I 
introduced the amino acid point mutations that disrupt the DNA binding function of the 
MLL CXXC domain into an MLL fusion protein.  I assessed the contribution of the MLL 
CXXC DNA binding function to MLL fusion protein function by assaying CXXC point 
mutant MLL-AF9 proteins in their ability to promote the immortalization of bone marrow 
cells in vitro, to promote leukemia development in vivo, to promote overexpression of 
Hoxa9, to protect target Hoxa9 CpGs from becoming DNA methylated, and to localize to 
Hoxa9.  I hypothesized that the DNA binding function of the MLL CXXC domain is 
critical to MLL fusion protein function.   
 In the second aim of my dissertation, domain swap experiments were designed in 
which the MLL CXXC domain was replaced with similar or different CpG DNA binding 
domains from other proteins in the context of an MLL-AF9 fusion protein.  These 
experiments help determine whether the MLL CXXC domain is unique in its ability to 
contribute to MLL fusion protein function, or if other protein domains can replace the 
MLL CXXC domain functionally.  We hypothesized that only those CpG binding 
domains that have the most similar known properties to the MLL CXXC domain, which 
include a conserved amino acid sequence and known DNA binding activity to 
unmethylated CpG DNA, would be able to function in an MLL fusion protein.   
 The results of this project find that the DNA binding function of the MLL CXXC 
domain is essential to MLL fusion protein function.  Because disruption of MLL CXXC 
DNA binding causes MLL fusions proteins to be unable to promote leukemia 
4 
development, this suggests that targeting the MLL CXXC domain with a small molecule 
inhibitor that inhibits DNA binding may serve as a potential novel therapy for MLL 
leukemia patients.  The CXXC domain swap experiments shed additional light onto the 
function of the MLL CXXC domain.  Two of the alternate CXXC protein domains 
studied here show binding to unmethylated CpG DNA, similar to the MLL CXXC 
domain.  However, only one of these alternate CXXC domains was able to function in an 
MLL fusion protein.  This suggests that the DNA binding function of the MLL CXXC 
domain is not the only essential function of this domain.  The MLL CXXC domain must 
contribute other functions to MLL fusion proteins, which may include recruitment of 
specific co-activator proteins, and this function is not retained in all CXXC domains. 
5 
CHAPTER 2 
LITERATURE REVIEW 
MLL Leukemia 
 The MLL (Mixed Lineage Leukemia) gene was first discovered due to its 
involvement in chromosome translocations that cause leukemia.3  Upon DNA damage, 
chromosome 11 at band q23 can undergo a double-stranded DNA break in the breakpoint 
cluster region within the MLL gene.  If a simultaneous double-stranded DNA break 
occurs, often in another chromosome, at one of many possible locations, the two different 
chromosome regions can fuse.  If the break occurs in-frame on the second gene, then the 
resulting translocation will encode an MLL fusion protein encompassing approximately 
1400 amino-terminal amino acids of the MLL protein fused to a C-terminal portion of a 
partner protein.  Over 60 different partner genes have been identified so far that can fuse 
to MLL.4  In addition to MLL translocations, the MLL gene can undergo mutations such 
as partial tandem duplications in which part of the gene is repeated within itself,13 
resulting in an abnormal MLL protein.  When MLL translocations or rearrangements 
occur in a bone marrow cell at a specific early stage of maturation, they promote the 
development of leukemia.  MLL translocations can cause acute lymphoid leukemia, acute 
myeloid leukemia or, rarely, a bi-phenotypic mixed lineage, or myeloid-lymphoid 
leukemia for which the gene is named.14 
 
6 
 
 MLL translocations are responsible for 5-10% of all human leukemias.2  While 
MLL translocations occur infrequently in adult de novo leukemias, they predominate in 
infant and in therapy-related leukemias which can develop in patients previously treated 
with DNA topoisomerase II inhibitors for another cancer.  As reviewed by Mohan et al, 
69-79% of infants with acute lymphoid leukemia (ALL) have MLL translocations, and 
this number increases to 90% among infants with congenital ALL.  At 35-50%, a smaller 
but still significant proportion of infants with acute myeloid leukemia (AML) have MLL 
translocations.  Among ALL patients, MLL rearrangements are a marker of poor 
prognosis, and infants with this disease have a significantly lower survival rate than those 
with non-MLL rearranged ALL.  Among patients with AML, which can be harder to treat 
than ALL, MLL involvement confers an intermediate risk.15  5-10% of MLL 
translocations are found in patients with therapy-related leukemias.2  MLL 
rearrangements account for the majority of therapy related leukemias that arise in patients 
who had been previously treated with DNA topoisomerase II inhibitors,16 but MLL 
translocations may also be caused by radiotherapy and other cancer treatments that 
induce DNA damage.2  The MLL therapy related leukemias, which have a short onset 
compared to other therapy related leukemias, most often present as AML, but can also 
appear as ALL, myelodysplastic syndrome, or chronic myelomonocytic leukemia.17  The 
fusion partner of MLL is often instructive as to whether ALL or AML develops in MLL 
patients.  The MLL-AF9 fusion is one of the more common MLL translocations.  It 
usually causes the development of acute myeloid leukemia, although a small percentage 
of patients with the MLL-AF9 fusion develop acute lymphoid leukemia.18  Overall, MLL 
7 
leukemia patients have a relatively poor prognosis,1, 19 so the development of effective 
targeted therapies would be beneficial for treating MLL leukemias. 
MLL Protein Domains 
 The MLL gene encodes a large, multi-domain protein (Figure 1A) that is involved 
in the maintenance of HOX gene expression during development and hematopoiesis.20   
The SET domain resides at the carboxy-terminus of MLL, and possesses histone 
methyltransferase activity, specific for lysine 4 on histone H3.21  The MLL transcriptional 
activation domain (TAD) also appears in the carboxy-terminal half of MLL, where it 
binds to the co-activator protein CBP,22 and has been shown to positively regulate gene 
transcription in reporter assays.23  The MLL protein undergoes post-translational 
cleavage into two fragments by the enzyme Taspase1.24  After cleavage, the 320 
kiloDalton (kDa) N-terminal fragment and 180 kDa C-terminal fragment of MLL 
associate noncovalently via their FYRN and FYRC domains.25  Several more 
characterized domains are present in the amino-terminal fragment of MLL.  Near the 
amino terminus of MLL, a specific interacting motif mediates binding to Menin and 
LEDGF;26 this interaction appears critical to MLL function and localization.27, 28  Also 
near the amino terminus of MLL are three AT hook motifs, which bind to A-T rich, bent 
DNA.23  The AT hook region of MLL also mediates binding to several proteins including 
SET, protein phosphatase 2A (PP2A), and GADD34.29, 30  Interestingly, MLL fusion 
proteins were seen to suppress the pro-apoptotic function of GADD34.30  Nuclear 
localization motifs target MLL to the nuclei of cells.31  The repression domain (RD) of 
MLL has been shown to downregulate expression of target genes in reporter-gene 
assays.23  The repression domain recruits histone deacetylases HDAC1/2 and other co- 
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Figure 1.  Protein Domains of MLL and MLL fusion proteins 
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(A) The full length MLL protein is cleaved by the enzyme Taspase1 into N-terminal and 
C-terminal fragments.  The C-terminal MLL fragment contains a SET domain which 
possesses methyltransferase activity specific to histone H3 at lysine 4, and a 
transcriptional activation domain.  The FYRC motif interacts with the FYRN motif of N-
terminal MLL to keep the two protein fragments of MLL dimerized.  The N-terminal 
MLL fragment contains a motif that interacts with DNA-binding proteins Menin and 
LEDGF.  Three AT hooks interact with AT-rich DNA.  SNL1 and 2 denote the speckle 
nuclear localization targeting motifs.  The CXXC domain interacts with unmethylated 
CpG DNA.  Four PHD domains and an atypical Bromodomain also appear in the N-
terminal fragment of MLL, but are not retained in MLL fusion proteins as they appear C-
terminal to the breakpoint cluster region at which the MLL gene undergoes chromosome 
translocations in MLL leukemia patients.  These translocations to partner genes result in 
the production of MLL fusion proteins (B). 
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repressor proteins including CtBP and the Polycomb group proteins BMI-1 and HPC2.32   
 
Recently, the MLL repression domain has also been shown to bind to the polymerase  
associated factor (PAF) complex, which functions in promoting transcription.33, 34  The 
DNA binding CXXC domain is within the repression domain and was identified by its 
homology to a region of DNA methyltransferase-1.35  The final domains in the amino-
terminal fragment of MLL include an atypical bromodomain and four plant 
homeodomain (PHD) zinc fingers.  These domains function in protein-protein 
interactions and are often identified in chromatin-associated proteins.36  The second PHD 
finger of MLL was shown to function in homodimerization and the third PHD finger 
mediates binding to trimethylated histone H3K4 and the cyclophilin CYP33.37, 38  MLL’s 
breakpoint cluster region of 8.3kb, just upstream of the region encoding the PHD fingers, 
is where the MLL gene undergoes translocations to partner genes in leukemia patients.39  
These translocations result in the loss of MLL’s PHD fingers, bromodomain, activation 
domain and SET domain and the gain of fusion partner protein domains (Figure 1B).   
MLL Function 
 MLL is an ortholog of the Drosophila trithorax gene, and so belongs to the 
Trithorax Group of proteins, which positively maintain target gene expression during 
development.  These proteins act in opposition to the Polycomb Group proteins which 
serve to downregulate the transcription of an overlapping group of target genes, including 
the HOX genes.40  Mll hypomorphic mutant mice were created by insertion of a lacZ 
cassette in exon 3b of the Mll gene, 3’ of the AT hooks, which caused loss of Mll 
expression.41  The null Mll-/- and heterozygous Mll+/- mice were used to determine the 
specific functions of MLL during development and hematopoiesis.  Mll-/- mice die during 
10 
embryonic development at embryonic day E10.5, indicating that MLL is an essential gene 
for life.41  Mll also shows haploinsufficiency, as Mll+/- mice were observed to be small at 
birth and show retarded growth.  These heterozygous mice also showed body segmental 
defects typical of homeotic transformations.41  In vitro differentiation assays using Mll-/- 
and Mll+/- progenitor cells from the yolk sacs of mouse embryos indicated that Mll is 
required during early hematopoiesis to maintain proper numbers of progenitor cells and 
to promote differentiation, but is not required for terminal differentiation of 
hematopoietic cells.42  Another study determined that Mll is required for the maintenance 
of target gene expression during early embyrogenesis.  Hoxa7 expression was activated 
but not sustained in Mll-/- embryos by day E9.43  The Mll-/- embryos showed phenotypic 
defects by day E10.5 including defects in the branchial arches and segmental boundaries.  
It was concluded that Mll is required for the development of multiple tissues during 
embryogenesis including skeletal, hematopoietic, neural, and craniofacial tissues.43   
 It is thought that MLL regulates transcription of target genes on the level of 
chromatin organization.44  The SET domain of MLL possesses histone methyltransferase 
activity specific for trimethylation of the histone H3 tail at lysine #4.21  This tri-
methylated H3K4 mark on histone tails acts as a mark of transcriptional activation.  It is 
up to some debate whether H3K4 trimethylation actively promotes transcription or is 
merely present as a marker for active genes.  It has been suggested that for MLL target 
genes specifically, the trimethylation of histone tails on H3K4 at the promoters of genes 
by MLL is necessary to recruit the pre-initiation complex or other factors necessary for 
activation of transcription.45 
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 The MLL protein contains many functional domains, which play a variety of roles 
themselves, but MLL does not act alone.  Besides the direct protein interactions mediated 
by the domains of MLL already mentioned, the MLL protein has been found in several 
large multi-protein complexes.  Two of these complexes were isolated from the K562 cell 
line, a non-MLL rearranged leukemia cell line.  The first complex isolated by Nakamura 
et al found MLL in a complex of at least 29 proteins.  These proteins include components 
of the TFIID transcriptional activation complex, the histone deacetylating NuRD and 
SIN3 complexes, the SWI/SNF ATP-dependent chromatin remodeling complex, and the 
Set1 protein complex that has histone H3K4 methylation activity.46  All of these proteins 
were found to be present on the promoter of MLL target gene HOXA9 when MLL was 
also present, suggesting a functional role of the complex in regulating MLL target 
genes.46  The second protein complex isolated by Yokoyama et al was much smaller.  
The only common elements between the two MLL complexes were the Set1 histone 
methyltransferase protein complex members WDR5 and RBBP5, which interact with the 
SET domain of MLL.47  Additional Set1 proteins Ash2L and HCF were also identified in 
this second MLL complex.  The final member identified in this MLL complex was 
menin,47 which binds to an N-terminal motif in MLL.26, 48  Menin is a DNA-binding 
protein49 and a tumor suppressor for multiple endocrine tumors.50  A third group isolated 
an MLL complex using an anti-WDR5 antibody in HeLa cells.51  They found some of the 
same proteins in the MLL complexes mentioned above, but also identified a MYST 
family histone acetyltransferase protein called MOF.  MOF specifically acetylates histone 
H4K16, and this activity was shown to be necessary for activation of the MLL target 
gene HOXA9.51      
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MLL Fusion Proteins 
 More than 60 MLL partner genes have been identified that fuse to MLL in MLL 
leukemia patients.4  Some MLL fusion partners are seen very rarely; several have only 
been documented in one patient.  As reviewed by Krivstov and Armstrong, partner genes 
fall into categories based on their known or proposed functions.  Fusions to cytoplasmic 
proteins account for about 10% of MLL rearranged leukemias.  These cytoplasmic 
proteins include EPS15, GAS7, EEN, and AF6.  All of these proteins have a coiled-coil 
oligomerization domain that is essential to confer leukemogenic activity when fused to 
MLL.52  More rare, at less than 1% of MLL leukemias, are MLL fusions to the septin 
family of proteins, including SEPT2, SEPT5, SEPT6, SEPT9/MSF, and SEPT11.  The 
septin proteins are also cytoplasmic and interact with cytoskeletal filaments, playing a 
role in mitosis.53  In those normally cytoplasmic proteins which have been studied, fusion 
to MLL causes the MLL-partner fusion proteins to become nuclear.  Another group of 
very rare MLL fusion partners are the nuclear histone acetyltransferase proteins including 
CBP and p300.54  The most common MLL partner genes, which account for greater than 
80% of MLL rearranged leukemias, encode nuclear proteins.  These include AF4, AF9, 
ENL, ELL, AF10, and AF5q31 and are thought to be involved in activation of the 
elongation step of transcription.17  The AF9 and ENL proteins are related and show high 
sequence homology to each other,55 while AF4 and AF5q31 belong to a family of 
proteins that also includes FMR2 and LAF-4, another rare MLL fusion partner.56 
 Different fusion partners, sometimes from the same functional group, are more or 
less common in pediatric versus adult MLL leukemias, or in the myeloid versus lymphoid 
phenotype of MLL leukemia.  For example, of MLL leukemias, MLL-AF4 accounts for 
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90% of adult ALLs, but only 34% of pediatric ALLs.  MLL-ENL is the second most 
common fusion in adult AMLs at 14%, and is common (24%) in pediatric ALLs, but is 
not seen in pediatric AML.17  Among therapy related leukemias, ELL is the most 
common MLL fusion partner, followed by AF10, AF9 and AF4 and others.2  Among all 
MLL-related ALLs, AF4 accounts for more than half of the MLL fusions, followed by 
ENL, AF9, AF10, AF6, and EPS15.5  There are more major fusion partners found in 
AML, but AF4 is rarely seen.57  The major AML fusion partners in decreasing order of 
appearance include AF9, AF10, ELL, AF6, ENL, AF17, AF1Q, SEPT6, and EPS15, 
which together account for 80% of MLL AMLs.5   
 Interestingly, while the fusion partners are often instructive as to the particular 
MLL leukemia phenotype, many of the most common fusion proteins interact with each 
other.  Specifically, MLL-AF4 almost always promotes ALL,57 and MLL-AF9 is more 
common in AML, but AF9 and AF4 proteins directly bind to each other, and this 
interaction is maintained in MLL-AF9 and MLL-AF4 fusion proteins.56  The AF9-AF4 
interaction proved essential for survival of MLL-AF4 and MLL-AF9 leukemia cells.58  It 
is unclear why AF9 and AF4 fusions would promote different types of leukemia when 
they colocalize to activate the same set of genes.  In addition to the AF9-AF4 interaction, 
several other proteins have been found to bind in a complex.  The super elongation 
complex, or SEC, identified by Lin et al, found AF5q31/AFF4 (a rare MLL fusion 
partner), AF4, ENL, ELL, AF9, and pTEFb proteins bound to MLL fusion proteins.59  
Similarly, Yokoyama et al identified a similar group of AF4, AF5q31, ENL, and pTEFb 
as the AEP, or AF4 family/ENL family/P-TEFb complex.60  It is hypothesized these 
elongation complex proteins are constitutively recruited to target genes by MLL fusion 
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proteins, which results in the inappropriate by-pass of a regulated step in transcriptional 
activation, over-expression of the target genes, and leukemia development.60  Several 
MLL fusion proteins including ENL, AF9, AF17, and AF10 have also been shown to 
interact in a complex with the histone methyltransferase enzyme Dot1L.61  Dot1L 
methylates histone tail residue H3K79, which is a mark of active transcription.62  It has 
been suggested that in the presence of MLL fusion proteins, the H3K79 methylation mark 
functionally replaces the H4K4 trimethylation mark normally deposited by the SET 
domain of MLL, which is lost in fusion proteins.  The presence of Dot1L has been shown 
to be essential to the survival of MLL fusion protein-expressing cells.63  
MLL Gene Targets 
 MLL has been well established as a regulator of HOX gene expression, but has 
more recently also been suggested to be a master regulator of transcription.  A genome-
wide ChIP-on-chip experiment was performed using MLL antibodies.  MLL was found at 
the promoters of over 5,000 genes, and was present at 90% of RNA Polymerase II 
occupied genes.64  92% of the MLL occupied regions also showed the MLL characteristic 
H3K4 trimethylation mark.64  These results suggest that MLL helps to regulate most 
genes that are transcribed by RNA Polymerase II.  This study conflicts with other reports 
however.  Milne et al performed conventional chromatin immunoprecipitation 
experiments using MLL and RNA Polymerase II antibodies on specific target genes.  
Promoters of genes such as Hoxa9, Hoxa7 and Meis1 showed binding of MLL and RNA 
Polymerase II in cells types in which those genes are expressed.  However non-MLL 
target genes including Gapdh, Hoxa1, Pbx1, Pbx3, and Mll itself showed RNA Pol II but 
not MLL binding.  The authors concluded from these experiments that MLL cannot be a 
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master regulator of transcription.65  In another study, Wang et al performed tiling arrays 
for H3K4 trimethylation, using Mll wild type and null mouse embryonic fibroblast 
(MEF) cells.  This study found that Mll was responsible for the H3K4 trimethylation 
marks of less than 5%, or a few hundred, of the genes that have this mark, including a 
subset of Hox genes.66  This report also supports the idea that MLL is responsible for the 
regulation of specific target genes. 
HOX Genes 
 HOX genes, which encode DNA-binding homeodomain-containing proteins, are 
evolutionarily conserved transcription factors that regulate developmental processes such 
as body segment identity and cell fates in developing embryos.67  In humans and mice, 
the HOX genes are present in four clusters: A, B, C, and D, which are located on four 
different chromosomes (Figure 2).  There are thirteen paralogous HOX genes, whose 
chromosomal order is evolutionarily maintained, though no one cluster contains all 
thirteen genes.  HOX genes are regulated spatially and temporally in developing embryos  
such that the more 3’ genes on their chromosomes are expressed earlier and toward the 
anterior side of embryos.  HOX gene expression patterns spread to the 5’ genes later in 
development and on the more posterior side of the embryo.67  HOX gene expression 
patterns also play an essential role in hematopoiesis. 68  Similar to the developing 
embryo, in general, more primitive bone marrow cells express the 3’ HOX genes while 
more mature bone marrow cells express 5’ HOX gens.70  MLL and Polycomb Group 
proteins act in opposition to each other on HOX genes to either activate or repress their 
expression, respectively.20   
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Figure 2.  Mammalian HOX gene clusters 
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The four mammalian HOX gene clusters are found on four different chromosomes.  
Genes at the 3’ ends of the clusters are expressed earlier in development and 
hematopoiesis than the 5’ genes.  Figure is adapted from Shah and Sukumar.69 
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HOXA9 Locus 
 HOXA9 is one of the most well-studied and important MLL target genes.  
Increased HOXA9 expression has been identified as an important marker of poor 
prognosis in AML.71  In addition, overexpression of HOXA9 by MLL fusion proteins has 
been shown to be critical to MLL leukemia development.72  Several transcripts arise from 
the HOXA9 locus.73  The conical transcript arises from exon CD which splices to exon II.  
An alternative exon AB was identified 4.5 kilobases upstream of the canonical HOXA9 
promoter.74  Exon AB is located in a region of high sequence homology across species6 
and encodes for a microRNA, mir196b.75  Several CpG islands appear throughout the 
HOXA9 locus.  Our laboratory has shown that MLL binds to a CpG island upstream of 
exon AB, and when MLL or an MLL fusion protein is present, a specific cluster of CpG 
residues are protected from DNA methylation which correlates with transcriptional 
activation of the locus.  When MLL is absent, DNA methylation levels in this region 
increase, and transcription of Hoxa9 and mir196b becomes repressed.6  
Chromatin and Epigenetics 
 The human genome consists of more than 3 billion base pairs of DNA, all of 
which must fit into the nuclei of every one of our cells in our bodies.  In order to do this, 
DNA is highly organized and compacted in complex with proteins into a structure called 
chromatin.  At its most compact, DNA forms the metaphase chromosomes typically seen 
in karyotypes.  Histone proteins primarily facilitate chromatin formation.  Two proteins 
each of H2A and H2B, and two each of H3 and H4 form tetramers that then associate 
with each other to form octamers of core histone proteins.76  146 base pairs of DNA wrap 
around the core histone particles to form a nucleosome.  Nucleosomes are spaced 20-60 
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base pairs apart, to form the 10 nm beads-on-a-string model of chromatin.  The linker 
histone H1 can then facilitate further compaction of the DNA and nucleosomes by coiling 
the chromatin into a 30nm diameter fiber.  Chromatin in these states is referred to as 
euchromatin, which includes regions on a chromosome where active genes are located.  
The 30 nm fiber chromatin can be quickly reverted to the 10 nm beads-on-a-string DNA. 
Genes in these regions are easily accessible to chromatin remodeling complexes that can 
slide nucleosomes to give transcription factors and polymerases access to the genes for 
transcriptional activation.77  Chromatin can be further compacted into heterochromatin to 
facilitate transcriptional repression.  Heterochromatic DNA regions include centromeres, 
telomeres, repetitive satellite sequences and the inactivated X chromosomes in females.78  
All DNA and chromatin becomes highly condensed during mitosis and meiosis.   
 Epigenetics refers to heritable changes to the genome that do not involve 
alterations of the genetic code.79  Epigenetic marks include DNA methylation and histone 
tail modifications such as acetylation, methylation, or ubiquitination.80  These 
modifications affect specific protein complex recruitment and DNA packaging into 
chromatin and results in a specific locus being more or less accessible to transcription 
factors and activation.  The histone code hypothesis proposed by Jenuwein and Allis 
describes how different epigenetic marks are recognized or “read” by specific protein 
domains and that it is the combination of epigenetic marks and recruited proteins on 
genes that leads to specific transcriptional states.  The authors propose that because 
epigenetic marks are heritable, they greatly extend the complexity and amount of 
information stored in our genomes, beyond that of our genetic DNA sequences.81  It is on 
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this epigenetic level that MLL and MLL fusion proteins function to activate their gene 
targets. 
DNA Methylation 
 When a cytosine nucleotide appears 5’ to a guanine nucleotide in a DNA 
sequence, this dinucleotide is termed CpG, for cytosine-phosphate-guanine.  DNA 
methylation occurs on the number five carbon of the cytosine ring of CpG 
dinucleotides.82  Because cytosine and guanine nucleotides base pair with each other, 
DNA methylation appears symmetrically on both complementary strands of DNA at 
CpGs.  This epigenetic mark appears on certain CpGs throughout the genome, resulting 
in a DNA methylation pattern that is associated with transcriptional repression.11  
Species-, cell-, and tissue-specific DNA methylation patterns have been documented, and 
the mark has been found to be involved in the regulation of gene transcription, cell 
differentiation, embryogenesis, imprinting, and silencing of mobile genetic elements.83  
Changes in DNA methylation patterns have been seen in cancers and other hereditary 
diseases.12  DNA methylation is also linked to chromatin modification, as proteins that 
bind to methylated CpGs recruit HDACs and other corepressors to inactivate chromatin.84  
The CpG dinucleotide is underrepresented in the eukaryotic genome because deamination 
of a methylated cytosine results in a transition mutation to thymine.  CpG islands, often 
appearing in the promoters of genes, are regions throughout the genome in which CpGs 
are not underrepresented.12  The CpGs in CpG islands are often unmethylated, which 
contributes to keeping the genes they are associated with transcriptionally active.  DNA 
methylation patterns are set by de novo DNA methyltransferase enzymes, DNMT3A and 
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DNMT3B, and the maintenance methyltransferase DNMT1, but DNA de-methylation is 
not well understood. 
 DNA methylation mediated repression of transcription can occur through several 
mechanisms.  As reviewed by Klose and Bird, in the promoters of genes, DNA 
methylation can inhibit binding of transcription factors to their DNA recognition site.  
Secondly, methyl-CpG binding proteins can bind via their methyl binding domain (MBD) 
to methylated DNA and recruit corepressors to silence gene transcription.  Third, DNA 
methyltransferases, which are enzymes that methylate CpG DNA, can recruit HDACs 
and histone methyltransferases to modify chromatin into a repressed state.  Finally, DNA 
methylation within a gene can inhibit RNA Polymerase II from binding and therefore 
inhibit transcriptional activation.11     
 It has recently been shown that a small percentage of CpGs are modified with 
hydroxymethyl groups.  TET1, a CXXC domain containing protein and a rare fusion 
partner of MLL, can enzymatically modify methylated CpGs, converting the residues to 
hydroxymethylcytosines.85  Common assays, such as bisulfite sequencing, for measuring 
DNA methylation do not distinguish between methylated and hydroxymethylated CpGs.  
However, recent studies have found this modification present in many cell types and 
correlating with active transcription suggesting this mark has an important functional role 
that is not yet understood.86      
Histone Tail Modifications 
 The amino-terminal ends of core histone proteins, called histone tails, protrude 
from compact nucleosomes, making them easily accessible to post-translational 
modifications.76  Acetylation of lysine residues in histone tails by histone 
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acetyltransferase, or HAT, enzymes such as CBP, p300, or MOF, is often associated with 
active gene transcription.80  Acetylated lysines in histone tails can be recognized by 
bromodomain-containing proteins such as chromatin remodeling proteins that help to 
facilitate transcription by relaxing the chromatin structure.80  Histone deacetylace or 
HDAC enzymes act to remove acetyl marks from histone tails.  Methylation of certain 
lysine residues in histone tails is performed by histone methyltransferase enzymes that 
contain SET domains, which are named for three founding genes that have this domain: 
Su(var)3-9, Enhancer of zeste, and Trithorax.87  Different methyltransferase proteins 
often have specificity to methylate specific lysine or arginine residues on histone tails, as 
they can have different functions.  In addition, lysine methylation can appear as mono-, 
di- or trimethlation, and each of these marks may be placed by different enzymes and 
have different functional outcomes.  For example, the Polycomb Group protein EZH2 
trimethylates histone H3K27, which is a mark of transcriptional repression.  H3K9 
trimethylation, catalyzed by the SUV39H and other proteins, is also a mark of repression.  
Methylation of H3K4 by MLL, Set1 and others, H3K36 by NSD1, and H3K79 by Dot1L 
are marks of activation.88  Chromodomain-containing proteins are one example of 
proteins that specifically bind to methylated histone residues.  For example, HP1 
recognizes methylated H3K9 via its chromodomain, and associates with the H3K9 
methylase SUV39H1 to propagate the methyl mark and cause spreading of 
heterochromatin.89  Histone tail methylation is not a permanent mark; enzymes such as 
LSD1 and Jumanji-domain containing proteins have been shown to demethylate specific 
lysine residues.90, 91  Additional histone tail modifications include phosphorylation of 
serine residues and ubiquitination of lysines.80         
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CpG DNA Binding Domains 
 Like histone tail modifications, DNA methylation status can also be can be “read” 
by specific protein domains.  The methyl-CpG binding domain, or MBD, specifically 
binds to methylated CpG DNA (Figure 3A).92, 93  MBD domains are found in the MBD 
family of repressor proteins which include MeCP2 and MBD1, MBD2, MBD3 and 
MBD4.94  All of the MBD-containing proteins can bind to methylated CpG DNA except 
MBD3, which has changes in the amino acid sequence of its MBD domain that prohibit 
binding.  The Kaiso protein is also known to bind to methylated DNA, though not 
through an MBD domain.  The zinc finger domains of Kaiso can bind to two methylated 
CpGs to mediate target repression.95   
 CXXC domains on the other hand, bind specifically to unmethylated CpG 
containing DNA9, 10, 96 (Figure 3B).  The name of the CXXC domain comes from the 
eight cysteine residues that have a highly conserved spacing throughout the domain 
(Figure 3C).  The domain folds into a saddle-like structure that loops around in such a 
manner that the cysteines coordinate two zinc ions, with four cysteine amino acids 
present around each ion.9  Structural data suggest that the domain interacts with target 
DNA such that a single CpG residue specifically forms hydrogen bonds with amino acids 
in the pocket of the domain, while a few DNA bases surrounding the CpG contribute 
non-specific electrostatic interactions.10  The first CXXC domain identified was in the  
DNA methyltransferase protein DNMT1.97  The MLL CXXC domain was identified by 
its homology to DNMT1,35 and since then CXXC domains have been found in proteins 
including CpG Binding Protein CGBP,98 repressor protein MBD1,99 histone H3K36 
demethylase FBXL11,100 and LCX/TET1, a rare fusion partner of MLL101, 102 that 
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Figure 3.  Structures of the MBD1 MBD domain in complex with methylated CpG 
DNA and the DNMT1 CXXC domain in complex with unmethylated CpG DNA and 
alignment of CXXC domains  
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(A) Stereo ribbon diagram of the solution structure of the MBD1 MBD domain in 
complex with methylated CpG DNA, with methyl groups shown in red.  Secondary 
structures are indicated.  Structure figure was adapted from Ohki et al.92  (B) Stereo 
ribbon diagram of the DNMT1 CXXC domain in complex with unmethylated CpG DNA, 
with the CpG shown in yellow and zinc ions shown in magenta.  Figure was adapted 
from Song et al.96 (C) CXXC domains are aligned to show amino acid sequence 
conservation: those identical in all, or present in two or more are shaded in dark and light 
grey, respectively.  Sequence of the MBD1 MBD is also shown. 
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hydroxylates methylcyotsines.85  CXXC domains are known to coordinate two zinc ions 
and most can specifically recognize and bind to one unmethylated CpG motif.9, 10, 96  By 
reading the DNA methylation status of a gene, CpG binding domains often play an 
important role in bridging DNA and histone modifications to cause further repression or 
activation of a gene locus. 
CpG DNA Binding Domain Proteins used in my research 
 CpG binding protein CGBP/CPF1/CXXC-1 is a transcriptional coactivator protein 
that binds to nonmethylated CpG DNA via its CXXC domain.98  CXXC-1 is an essential 
gene, as null mice embryos die shortly after implantation.103  The CGBP protein localizes 
to nuclear speckles in the cell and binds to the nuclear matrix.104 CGBP is thought to be 
involved in global DNA methylation patterning during embryogenesis,105 probably 
through its interaction with DNMT1.106  Besides its CXXC domain, CGBP also contains 
plant homeodomains (PHD), acidic and basic domains, and a coiled-coil domain (Figure 
4A).98  CGBP has been shown to interact with H3K4 histone methyltransferase proteins 
MLL1, MLL2, and hSET1, and may play a role in regulating certain MLL target 
genes.107  CGBP also interacts with and helps direct the genomic targeting of H3K4 
methyltransferase Setd1A,108 and thus helps to bridge DNA and histone modifications.  
DNMT1 is the maintenance DNA methyltransferase enzyme that specifically methylates 
hemimethylated DNA.109  DNMT1 is present at the replication fork during S phase and  
provides the methyl mark to the unmethylated strand of newly replicated, 
hemimethylated DNA in order to propagate the epigenetic mark.110  The DNMT1 protein 
contains a DNA binding CXXC domain, an enzymatic methyltransferase domain, a 
replication focus-targeting domain, a nuclear localization signal, and two bromo-adjacent  
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Figure 4.  CXXC Domain containing Proteins 
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(A)  The human CGBP protein schematic was adapted from Lee et al. 2001.  CGBP 
contains two PHD domains, a coiled-coil domain, acidic and basic stretches and a DNA-
binding CXXC domain.  (B)  Schematic of mouse DNMT1, which has 85% amino acid 
sequence identity to human DNMT1, was adapted from Song et al 2010.  DNMT1 has a 
replication foci-targeting domain (RFD), a nuclear localization signal (NLS), a DNA-
binding CXXC domain, two bromo-adjacent homology (BAH) domains, and a C-
terminal methyltransferase domain that has specificity for the unmethylated strand of 
hemimethylated DNA.  (C)  Mouse Mbd1 splice variant isoforms were adapted from 
Jorgensen et al 2004.  Several isoforms of human MBD1 also exist, similar to the mouse 
proteins shown here.  MBD1 contains a methyl-binding domain (MBD), a transcriptional 
repression domain (TRD), and two or three CXXC domains, depending on the splice 
variant.  In MBD1, CXXC-3 binds to unmethylated CpG-DNA, but the CXXC-1 and 
CXXC-2 domains are unable to bind to DNA. 
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homology (BAH) domains (Figure 4B).  While it was once suggested that the CXXC 
domain of DNMT1 could recognize the hemimethylated DNA target of the enzyme, it 
was more recently shown to interact with unmethylated DNA, similar to most CXXC 
domains96 (Figure 3B).  The DNMT1 CXXC domain is now thought to play an auto-
inhibitory role such that when it encounters unmethylated CpG DNA, the CXXC domain 
recognizes and binds to it, thereby protecting it from becoming methylated by the 
adjacent enzymatic domain.96   
 MBD1, a member of the methyl-CpG binding protein family, is a co-repressor 
protein known to bind to methylated DNA via its MBD domain.94  MBD1 also contains 
two or three CXXC domains, depending on the splice variant (Figure 4C).93  From 
murine Mbd1, the first two CXXC domains were shown to be unable to bind to CpG 
DNA, regardless of methylation status,111 but do interact with the Polycomb repressive 
complex 1 (PRC1) protein Ring1b.112  Mbd1’s third CXXC domain can bind to 
nonmethylated DNA111 and also interacts with PRC1 protein hPc2.112  MBD1 also 
interacts with histone H3K9 methyltransferase enzymes SETDB1113 and Suv39h1, which 
also recruits HDACs.114  These interactions between MBD1 and Polycomb group 
proteins and other chromatin modifying proteins show the importance of coupling DNA 
methylation to chromatin remodeling for gene repression.  It is also known that MBD1 is 
present at the replication fork during S phase, through its interaction with the p150 
subunit of chromatin assembly factor 1 (CAF-1).115  CAF-1 binds to histone proteins H3 
and H4 to reassemble nucleosomes following DNA replication.116  Both DNMT1 and 
CAF-1 proteins are present at the replication fork via their interactions with PCNA 
(proliferating cell nuclear antigen).110, 115  After DNMT1 provides the methyl mark on 
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newly replicated DNA, MBD1 can bind directly to the methylated DNA, facilitating 
repression through recruitment of histone methyltransferases and histone deacetylases. 
MLL CXXC Domain 
 The CXXC domain of MLL was initially identified by its homology to DNMT135 
and was first shown to bind specifically to unmethylated DNA through electrophoretic 
mobility shift assays.117  Because it is a DNA binding domain, the MLL CXXC domain 
was initially thought to function in contributing to the targeting of MLL and MLL fusion 
proteins to the genes that they regulate.  Through deletion and point mutation 
experiments, the presence of the MLL CXXC domain was shown to be essential to MLL 
fusion protein function in colony formation assays.8  In the study by Ayton et al, the 
conserved cysteine residues of the MLL CXXC domain were mutated to alanines,8 which 
would disrupt zinc coordination and appropriate folding of the CXXC domain.9, 10  From 
this, we can conclude that an intact CXXC domain is essential to MLL fusion protein 
function, but nothing can be concluded about the DNA binding function of the MLL 
CXXC domain as this function would be lost when the domain does not fold properly.    
Our laboratory has shown that MLL binds to a region at the 5’ end of the Hoxa9 locus 
within a CpG island, and that a subset of these CpGs is protected from DNA methylation 
when MLL or MLL fusion proteins are present.6  As it is known to bind to unmethylated 
CpG DNA, we hypothesized that this methylation protection function could be facilitated 
by the MLL CXXC domain.  By protecting the target DNA from methylation, the CXXC 
domain may help to keep the Hoxa9 locus in an active state. 
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CHAPTER 3 
 
METHODS 
 
Cloning of MSCVneo-MLL-AF9-Flag CXXC Domain Swap and Point Mutant 
Constructs 
 
 In order to swap CXXC point mutations and alternate CpG binding domains 
efficiently into MLL-AF9, I generated a modified version of our MSCVneo-MLL-AF9-
Flag construct.  I introduced a BamHI restriction site at the carboxyl end of the MLL 
CXXC domain (amino acid 1201; one glycine added) and removed an endogenous 
BamHI site at amino acid 1251 (no amino acid change) to facilitate domain swapping 
(see Appendix A).  In order to do this, the 5’ MLL fragment (4086 base pairs) from a 
plasmid encoding MSCV-MLL-ELL fusion had been isolated by a previous graduate 
student (Donna Santillan) using the restriction enzymes EcoRI, which cuts at the 5’start 
of MLL, and SalI, which cuts at the 3’ end of the fragment of MLL.  This is the 5’ MLL 
fragment which is included in MLL fusions proteins and encompasses a sequence 
corresponding with MLL amino acids 1-1403.  All Restriction digests were carried out 
for 1-2 hours for plasmid DNA or overnight for PCR products, at 37° Celsius, and were 
followed by heat inactivation at 65° Celsius for 15 minutes.  If the digest was performed 
on a vector, the linearized vector was treated with 1ul calf intestine alkaline phosphatase 
(NEB) for 30-60 minutes at 37° Celsius to prevent internal religation of the vector.  All 
digests were followed by gel purification using Qiaex II beads (Qiagen).  I ligated this 4.1 
KB DNA fragment of MLL into a pMCS5 holding vector that I had digested with EcoRI
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and SalI.  All ligations were carried out using 3:1 molar ratios of insert to plasmid, in 
10ul reactions using 1ul T4 DNA ligase (Invitrogen), overnight at 14° Celsius.  1μl of 
ligation mix was then transformed into 50 μl of Library Efficient DH5α bacteria cells.  
Mini-preps of DNA from transformed bacterial colonies were performed, and correct 
DNA ligation was verified by restriction digest.   
 Next I performed a series of restriction digests, PCRs, and ligations in order to 
move the BamHI site in MLL from the corresponding amino acid site 1250 to 1201.  
Primer sequences are listed in Table 1.  First I digested the pMCS5-5’MLL plasmid with 
BamHI, which linearized the DNA with a cut at the site of amino acid 1250.  With an 
undigested plasmid, I next PCR amplified MLL from aa site 1201 to aa site 1250, 
creating with the primers a BamHI site at 1201, and a BglII site at 1250.  PCRs for 
cloning were carried out with Pfu polymerase in order to ensure high fidelity of 
amplification.  When DNA is digested with BglII, it creates the same overhangs that 
BamHI creates, allowing two pieces of DNA that have been digested with each of the two 
enzymes to be ligated onto each other.  This creates a hybrid site that destroys the ability 
of either enzyme to cut at that site.  This allowed me to destroy the 1250 BamHI site 
without altering the amino acid sequence produced by the codons involved in this area.  I 
then digested the PCR products with BamHI and BglII and ligated this fragment into the 
BamHI digested pMCS5-5’MLL.  This created a plasmid with the DNA corresponding to 
aa1201-1250 being present two adjacent times, but with the second aa1250 BamHI site 
now a hybrid BglII/BamHI site.  In order to delete the duplicated DNA, I next returned to 
the unmutated pMCS5-5’MLL plasmid, and PCR amplified the CXXC domain region 
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corresponding to amino acids 1150 to 1201.  The endogenous AatII site was included in 
the amplified products, and a BamHI site was added with the reverse primers to appear at 
amino acid site 1201.  This BamHI sequence inserted with the primers caused an extra 
amino acid, glycine, to be introduced into the translated protein.  As this glycine appears 
C-terminal to the structured part of the CXXC domain, it was not expected to change the 
function of the CXXC domain or MLL.  Next, these PCR products and the engineered 
MLL plasmid containing the duplicated DNA were digested with AatII and BamHI.  This 
digest removed the DNA sequence corresponding to amino acids 1150-1201 (the CXXC 
domain) as well as the original 1201-1250 site, but not the PCR amplified region from 
aa1201-1250 added in the last ligation that has the destroyed BamHI site.  The AatII and 
BamHI digested PCR products and vector were then ligated to each other to create the 
new BamHI site at amino acid 1201.  This produced a DNA sequence that encodes 
5’MLL with AatII and BamHI restriction sites flanking the MLL CXXC domain.  This 
clone was sequenced and this altered MLL-AF9 fusion protein was also later verified to 
transform mouse bone marrow cells with the same capacity as unmodified MLL-AF9.   
Table 1.  Primers used to generate MSCV-MLL-AF9-Flag construct with alternate 
BamHI restriction site to use for swapping the CXXC domain 
 
Amplicon Primers (5’ to 3’) 
MLL (aa1201BamHI-
1250BglII) 
Forward: CGGGATCCAAAGCCTACCTGCAGA 
Reverse: GAAGATCTTCTCTTGCTGATGGGGTAGG 
MLL (aa1150AatII – 
1201BamHI) 
Forward: GGGACGTCGATCGAGGCG  
Reverse: CGGGATCCAGGCATCCATTGTAGATTCTGAC 
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Table 2.  Primers used to amplify CXXC or CpG-Binding Domains for substitution 
into MLL-AF9 
 
Amplicon Primers (5’ to 3’) 
MLL CXXC (point 
mutations) 
Forward: GGGACGTCGATCGAGGCGGTGT 
Forward: GGGACGTCGATCGAGGGCGTGT (For R1154A) 
Reverse: CGGGATCCAGGCATCCATTGTAG 
DNMT1 CXXC Forward: GGGACGTCGAAAGCGCCGGCGATGTG Reverse: CGGGATCCCTTCATGGCCATATTGGGAC 
CGBP CXXC Forward: GGGACGTCGAAAACGGTCAGCCCGCATGT Reverse: CGGGATCCCGATTCCCGGGCCCGCAG 
MBD1 CXXC Forward: GGGACGTCGAAAGCGTGTGGGCTGTGGGGAG Reverse: CGGGATCCCCTTTCCACAATCCGGAGGC 
MBD1 MBD Forward: GGGACGTCGAATGGCTGAGGACTGGCTGGAC Reverse: CGGGATCCCTTGGGGGCTGGATAGCA 
 
The endogenous AatII restriction site at the N-terminus of the MLL CXXC domain 
(amino acid 1150), and the engineered BamHI site (amino acid 1201) were next used to 
swap point mutation containing MLL CXXC domains or alternate CXXC or MBD 
domains into MLL-AF9.  MLL CXXC (amino acids 1147-1203) with point mutations 
R1154A, Q1187A, C1188D, C1188A, or K1185A were provided in pGex vectors by 
Bushweller Lab.  I amplified these point mutant domains with primers that included the 
endogenous AatII site in the forward primer and an added BamHI site in the reverse 
primer (Table 2).  The R1154A construct required a forward primer that contained this 
mutation as it appears near the N-terminus of the CXXC domain.  The primers listed in 
Table 2 were also used to amplify the following domains:  DNMT1 (NM_001379) (TB 
MeTase in PcDNA3.1 from Moshe Szyf) CXXC domain (amino acids 649-697), CGBP 
(NM_001101654) (pBS-CGBP from David Skalnik) CXXC (amino acids 163-215), 
MBD1 transcript variant 1 (NM_015846) (amplified from genomic DNA) CXXC (amino 
acids 172-221), and MBD1 transcript variant 1 (NM_015846) (pCS2-5MT-MBD1 from 
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Adrian Bird) MBD (amino acids 1-75).  Following PCR, the PCR products and the 
pMCS5-5’MLL with altered BamHI site were digested with AatII and BamHI and gel 
purified.  Ligations were performed to introduce the point mutant MLL CXXC or 
alternate CpG-Binding domains into 5’-MLL.  Plasmids were transformed then 
sequenced.   
 With regards to the MBD1 MBD domain, its DNA sequence contained a BamHI 
restriction site within the region we wanted to amplify.  In order to be able to use the 
same cloning scheme for this domain as for the others, I performed a site-directed 
mutagenesis on the MBD domain prior to ligation into MLL.  The MBD domain was 
amplified with the primers listed in Table 2, then the PCR products were cloned into a 
pCR2.1 TOPO TA cloning vector following kit protocol, and the product was sequenced.  
Next, site directed mutagenesis (Stratagene) was performed in order to destroy the 
BamHI site in the MBD domain, while preserving the amino acid sequence produced 
from this site.  Primers are listed in Table 3.  Mutated DNA was transformed into XL-1 
Blue bacterial cells and cells were plated on LB agar containing X-gal for blue-white 
selection according to protocol.  Following sequencing, the MBD domain was digested  
out of the Topo vector with AatII and BamHI, and ligated into 5’MLL as described 
above. 
Table 3.  Primers for site-directed mutagenesis of MBD1 MBD 
 
Amplicon Primers (5’ to 3’) 
pCR2.1 Topo- 
MBD1 MBD 
Forward:GCCCCACAGGAGACAGAATCCGAAGCAAAGTTGAG 
Reverse: CTCAACTTTGCTTCGGATTCTGTCTCCTGTGGGGC 
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 Following the generation of CXXC point mutations or domain swaps into 5’MLL, 
three way ligations were performed to create MSCVneo-MLL-AF9-Flag constructs.  The 
pMCS5-5’MLL plasmids with altered CXXC domains were digested with EcoRI and 
SalI and the 5’MLL fragments were gel purified.  To obtain the AF9-Flag fragment, 
MSCVneo-MLL-AF9-Flag was digested with SalI and Blg2, and the 300 base pair band 
was gel purified.  A purifed SalI/EcoRI digested MSCVneo vector was obtained from a 
previous lab member (Amanda Ryan).   Three-way ligations were performed overnight 
then 1μl was transformed into electrocompetent eDH5α cells by electroporation at 310 
volts.  All constructs were sequenced. 
Cloning of GST-tagged CXXC and MBD Domain Proteins 
 
 Isolated CXXC or MBD domains were cloned into the pGex-4T1 vector.  The 
designs of the domains were based off of our published work with the Bushweller Lab 
using 57 amino acids of the MLL CXXC domain (1147-1203) to solve the structure of 
the domain with DNA.10  Primers for the CXXC domains were designed to include the 
same number of amino acids before and after the CXXC cysteines as were used from 
MLL CXXC, and 75 amino acids for the MBD domain, as was previously used to solve 
the MBD domain structure.92  Primers are listed in Table 4 and amplified DNMT1 
(NM_001379) CXXC amino acids 645-700, CGBP (NM_001101654) CXXC amino 
acids 161-217, MBD1 transcript variant 1 (NM_015846) CXXC-1 amino acids 168-224, 
and MBD1 (NM_015846) MBD amino acids 1-75.  BamHI or BglII (for MBD1 MBD) 
restriction sites (in forward primers) and EcoRI restriction sites (in reverse primers) were 
used to clone the PCR products into the pGex4T1 vector.  All clones were confirmed by 
sequencing.   
34 
Table 4.  Primers used to amplify CpG-Binding Domains for creation of GST fusion 
proteins 
 
Amplicon Primers (5’ to 3’) 
DNMT1 CXXC Forward: CGGGATCCGAGAACGCCTTTAAGCGC  Reverse: CGGAATTCATCTGCCTCCTTCATGGCC 
CGBP CXXC Forward: CGGGATCCCAGATCAAACGGTCAGCC  Reverse: CGGAATTCCTTGTACGATTCCCGGGC 
MBD1 CXXC Forward: CGGGATCCCAGAGAATGTTTAAGCGTGTG Reverse: CGGAATTCCCCTCGGCTCCTTTCCAC 
MBD1 MBD Forward: GAAGATCTATGGCTGAGGACTGGCTG Reverse: CGGAATTCCTTGGGGGCTGGATAGCAC 
 
Bacterial Expression and Column Purification of GST-tagged CXXC and MBD 
Domain Proteins 
 
 GST-CpG Binding Domain constructs were transformed into BL21(DE3)pLysS 
bacterial cells (Stratagene).  Starter cultures (4 flasks of 100mLs each per construct) were 
grown overnight in LB in the presence of ampicillin and chloramphenicol at 37°C 
shaking at 225 rpm.  Cultures were expanded (into 4.4 liters total per construct) and 
allowed to grow for 8 hours at 37°C, then were induced with 1mM IPTG overnight at 
room temperature.  Cells were pelleted at 6000 rpm in a JA-10 rotor, then lysed with 
50mM Tris, pH 7.2, 400mM Sodium Chloride, 50μM Zinc Chloride, 1mM DTT, 1mg/ml 
lysozyme, 0.25mg/ml PMSF.  Lysates were sonicated at 60% power on ice with stirring 
for 15 minutes using cycling of 30 seconds on, 30 seconds off.  Cell debris was pelleted 
at 12,000 rpm (21,000 x g) using at JA-18 rotor for 1 hour at 4°C, followed by filtration 
of the supernatant, or debris was pelleted using an ultracentrifuge at 20,000 rpm (30,000 
x  g) for 30 minutes at 4°C.  Soluble GST-tagged CXXC proteins were isolated using 
Glutathione agarose beads (Fluka 49739).  Proteins were allowed to bind the column 
overnight, rocking at 4°C.  After washing (50mM Tris, pH 7.2, 400mM Sodium Chloride, 
50μM Zinc Chloride, 1mM DTT), GST-CXXC or GST-MBD proteins were eluted with 
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10mM Glutathione (G4251, Sigma, St. Louis, MO) in wash buffer.  Protein purity was 
verified by Coomassie Blue staining.  
DNA binding experiments using Fluorescence Polarization (FP) 
 Unmethylated C-terminal fluorescein labeled DNA (5' GGGTCGCGGGAG 3', 
Integrated DNA Technologies) and the purified GST-tagged CXXC or MBD domains 
were dialyzed into FP buffer (50mM Tris-HCl, 150mM KCl, 1mM DTT, 10uM ZnCl2). 
Fluorescein labeled DNA was added to 96-well black COSTAR (Corning Life Sciences, 
Lowell, MA, USA) plates. The proteins were separately mixed with fluorescein labeled 
DNA and serially diluted 1:2 onto the DNA-containing COSTAR plates. The plates were 
incubated in the dark at room temperature for 1 hour. A PHERAstar microplate reader 
(BMG Labtech, Durham, NC, USA) was used to measure fluorescence polarization with 
excitation at 494 nm and emission at 525 nm. The DNA binding experiments were 
performed three times. To calculate Kd for each protein, anisotropy values (mA) were 
plotted versus the log of protein concentration (µM), and the resulting plots were fit to a 
one-site sigmoidal binding curve using Origin 7.0 (MicroCal, Northampton, MA, USA).  
Final FP experiment included in this study was performed by Aravinda Kuntimaddi. 
Immunoprecipitation and Western Blot Analysis 
 
 Phoenix-Eco cells (Garry Nola, Stanford CA / Orbigen) were harvested three days 
after transfection with MSCV-MLL-AF9-Flag or domain swap constructs.  Cells were 
lysed with RIPA buffer (50mM Tris, 150mM NaCl, 1% Triton X, 0.1% SDS, 1% Na-
deoxycholate) containing Protease Inhibitors (Sigma, St. Louis, MO) at 1:100 for 10 
minutes on ice.  Lysates were sonicated briefly, then insoluble material was removed by 
centrifugation at 14,000 rpm for 30 minutes at 4°C.  Anti-Flag M2 affinity gel (Sigma) 
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was washed with PBS-Tween, then beads were resuspended in RIPA buffer with Protease 
Inhibitors.  Cell lysates were incubated overnight with anti-Flag beads at 4°C with 
rotation to immunoprecipitate MLL fusion proteins.  Proteins were eluted by boiling 
samples in SDS sample buffer at 95°C for 5 minutes, then were resolved by SDS-PAGE 
on a 5% gel.  Proteins were transferred for 2 hours at 70 volts to PVDF (Millipore) 
membranes using 1X CAPS transfer buffer with 10% methanol (10X CAPS buffer: 
100mM CAPS, 0.1% SDS, pH = 11).  Membranes were blocked in 5% milk for one hour 
up to 2 days.  MLL fusion proteins were detected by staining with anti-Flag (M2) 
antibodies (Sigma) in 3% milk at 1:1000 dilution for 2-2.5 hours at 4°C, followed by 
three 5 minute washes with PBS-0.05% Tween, then secondary anti-mouse-HRP 
(Amersham, Pittsburgh, PA) at 1:3000 in 3% milk for 2 hours, and three 15-20 minute 
PBS-Tween washes.  Blots were rinsed with water then developed with ECL 
(Pierce/Thermo Scientific Rockford, IL).   
Retrovirus Production 
 Phoenix-Eco cells (Garry Nolan / Orbigen) were grown in DMEM 10% FBS 1% 
Pen/Strep.  Four million cells per dish were plated into five 10cm dishes one day prior to 
transfection.  Using CalPhos Mammalian Transfection Kit (Clontech, Mountain View, 
CA), the cells were transfected with 25μg of DNA per 10cm dish. Sixteen hours post-
transfection, media was removed from the cells and 7ml of fresh media added. Cells were 
put into a 32°C incubator with 5% CO2.  The following day, media was collected from 
the cells.  An additional 7ml of the media was added to the cells and the dishes were 
returned to the 32°C incubator.  Media was collected again 48 hours post-transfection and 
combined with the media already collected, then spun down to remove any cell debris.  
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Retroviruses were concentrated about 6x using Centricon Plus 70 filters (Millipore) by 
centrifugation in a swing bucket JS 7.5 rotor.  Concentrated retrovirus was aliquoted, 
snap frozen, and stored at -80° Celsius. 
Retroviral Titering 
 2.5x104 Rat-1A cells per well were plated in a 6 well dish a day before infection.  
Serial dilutions of retroviruses (1:2 up to 1:1x106) in 1mL DMEM 10%FBS were added 
to cells with 16mg/mL polybrene.  Cells were incubated for 2 hours at 37oC 5%CO2, then 
1ml DMEM 10%FBS was added to each well.  Cells were incubated for 24h at 37oC 
5%CO2. Media was removed then replaced with 2ml DMEM 10%FBS with 0.5mg/mL 
G418 to select for cells that had taken up the virus.  Cells were kept under selection for 
10 days, then washed with PBS and stained with 1mL of a solution of 0.1 gram 
methylene blue in 60 mL Methanol for 5 minutes.  Plates were rinsed and dried, then 
colonies were counted.  Ideal titers were in the 1x105 to 1x106 virus particles/mL range, 
but lower titers were acceptable if larger volumes of virus were used for infection.  
Primary Mouse Bone Marrow Isolation 
 One C57Bl/6 mouse, age 8-12 weeks, was sacrificed by CO2 inhalation. Tibias 
and femurs were collected in a cell culture dish with RPMI 2%FCS on ice.  Working in 
the hood, excess tissue was removed from bones with sterile gauze.  8 mL RPMI 2% FCS 
was added to a 10cm plate on ice.  Using a 25 gauge 1.5” needle and media in the dish, 
bone marrow was flushed into the plate until bones appeared white.  Cells were spun 
down at 1500 rpm for 5 min at 4°C, then resuspended in 5mL 1X cold sterile red cell 
lysis buffer (10X RBC lysis buffer: 83 grams NH4Cl, 10 grams NaHCO3, 0.37 grams 
EDTA in 1 liter H20) and incubated on ice for 5 min. Cells were spun down at 1500 rpm 
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for 5 min at 4°C, then resuspended in 10 ml PBS 2%FCS to create a single cell 
suspension to count the cells. 
C-Kit Positive Selection of Mouse Bone Marrow Progenitor Cells 
 To select for the c-Kit+ progenitor cells in the mouse bone marrow, I followed the 
Easy Sep Mouse CD117 (c-Kit) Positive Selection Kit (#18757 Stem Cell).  Cells were 
resuspended at 100 x 106 cells per ml in PBS 2% FBS, in a Falcon 5ml Polystyrene 
Round-Bottom Tube.  CD117 antibody (with Fc blocker) was added to cells at 70ul/ml 
cells.  Solution was mixed and incubated at room temperature for 15 minutes.  Easy Sep 
PE selection Cocktail was added at 70μl/ml cells.  Solution was mixed and incubated at 
room temperature for 15 minutes. Magnetic nanoparticles were mixed by pipetting 5 
times, then added to the cell solution at 50μl/ml cells.  Solution was mixed and incubated 
at room temperature for 10 minutes.  Cell suspension was next brought up to 2.5mL with 
PBS 2% FBS. Cells were mixed by pipetting 2-3 times.  Tube without cap was placed in 
chilled Easy Sep magnet and let sit for 5 minutes in hood.  Holding tube in the magnet, it 
was inverted and supernatant was allowed to pour into waste tube.  Tube was removed 
from magnet and 2.5 mL PBS 2%FBS was added to cells, pipetting 2-3 times to mix.  
Magnet separation was repeated for a total of four 5 min separations.  Cells were 
resuspended in 1.5mL PBS 2%FBS and counted. Cells were plated overnight in a round 
bottom 96 well dish at 1 million per 1 mL of RPMI 1640 media with 10% FBS, 1% Pen-
Strep, and supplemented with 0.05 mM β –mercaptoethanol (Sigma), 100ng/ml SCF, 
10ng/ml IL3, and 10ng/ml IL6.  Sterile H20 was added to wells surrounding cells to keep 
them from drying out. 
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Retroviral Transduction 
 C-Kit+ cells were infected with MSCV-MLL-AF9-Flag or CXXC mutant- 
expressing retroviruses or vector control on two consecutive days. 30,000 c-Kit+ cells 
were centrifuged with 750ul of retrovirus, 7.5μl of 100mM HEPES, 1μl of 4mg/ml 
polybrene (Sigma) and RPMI 1640 10%FBS to bring volume to 1mL in Beckman GS-
6KR centrifuge at 33°C for 4 hours.  Double amounts of virus and reagents were used if 
virus stocks were of low titer.  After the first day of spinoculation, cell were cultured in 
96 well round bottom dish in RPMI 10% FBS, 1% Pen/Strep, 0.05 mM β-
mercaptoethanol (Sigma), 10ng/ml of IL-3, 10 ng/ml of IL-6 and 100ng/ml of SCF. Cells 
were grown overnight at 37°C in 200μl of media. 
Colony Assays 
 Following the second day of spinoculation, cells were plated at a concentration of 
1,000 to 10,000 cells per 35mm petri dish, depending on transformation potential, in 
methylcellulose (Stem Cell M3234). Methylcellulose was supplemented with glutamine, 
10ng/ml of IL-3, 10ng/ml of IL-6, 100ng/ml of SCF and 10ng/ml of GM-CSF. For 
selection of infected cells, G418 was added at concentration of 1.25mg/ml for the first 
week. Cells were grown in humid chambers consisting of a 15cm dish containing an 
uncovered 35mm dish holding sterile water. After one week, colonies were counted, then 
broken up by pipetting, and the total number of cells were determined. Cells were 
replated at 1-10,000 cells per 35mm dish for four weeks or until cell numbers were too 
low to replate.  Experiments were repeated at least 6 times.  Pictures of colonies in 
methylcellulose were taken through air on a Leica model DMIL microscope (Wetzlar, 
Germany), through a 4x/0.10 NA lens, with a Canon PowerShot S40 digital camera. 
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Images were acquired with Canon ZoomBrowser EX, version 8.  Using week 4 colony 
number means, statistical significance was determined by performing two-sample t-tests 
with a p-value cutoff of 0.05.  All constructs were tested for a significant increase in 
colony number as compared to MSCVneo and a significant decrease in colony number as 
compared to MSCV-MLL-AF9.   
Cytospins 
 50 – 200,000 colony assay cells were spun onto poly L-lysine coated slides 
(Scientific Device Laboratory, Des Plaines, IL) at 22,000 rpm for 15 minutes using a 
Cytofuge (StatSpin Technologies, Norwood, MA) and stained with Hema 3 (Fisher 
Scientific).   
Leukemia Assays 
 Bone marrow cells were collected from 5-6 week old B6.SJL (CD45.1+) mice, 
and c-Kit positive progenitor cells were isolated and infected with retrovirus as described 
above.  C57Bl/6 recipient mice were exposed to 9 Gy radiation from a Gammacell 40 
machine.  Subsequently, 1.5 – 2 x105 of the B6.SJL cells (above) plus 2x105 whole bone 
marrow cells (C57Bl/6 rescue cells), were injected retroorbitally into recipient mice.  To 
monitor for disease progression, mice were examined 3-5 times per week for signs of 
illness, and peripheral blood samples were obtained once per month.  Complete blood 
counts were measured with a Hemavet 950 (Drew Scientific, Oxford, CT).  In addition, 
expansion of the CD45.1+ blood cell population was monitored by flow cytometry.  Sick 
mice were sacrificed by CO2 inhalation.  Spleen, heart, lung, kidney, and liver tissues 
were fixed in buffered formalin then were sent to be sectioned and stained with 
hematoxylin and eosin in the core histology facility.  Peripheral blood and bone marrow 
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smears were stained with Hema 3 stain (Fisher Scientific).  Flow cytometry on peripheral 
blood and bone marrow cells was performed as described below.  All experiments on 
mice in this study were performed with the approval of and in accordance with the 
Loyola University Medical Center Institutional Animal Care and Use Committee, in 
accord with Federal guidelines.  Pictures of bone marrow and blood smears were taken 
on an Olympus BH-2 microscope (Tokyo, Japan), under a 100x/1.25 NA oil-immersion 
lens, with a Sony 3CCD camera, model DXC-76OMD.  Pictures of organ sections were 
taken through air with a 10x/0.25 NA lens on the same microscope.  Images were 
acquired with Adobe Premier software, version 4.2.1.  All images were processed using 
Adobe Photoshop CS3, version 10.0. 
Flow Cytometric Analysis of Leukemic Cells 
 Peripheral blood and bone marrow samples (1-5x106 cells) from mice were 
resuspended in 5 ml PBS 2%FBS, then spun down. Supernatants were removed, then 
cells were resuspended in 5 ml of 1X RBC lysis buffer. Cells were incubated for 5 
minutes, then spun down and washed with 5 ml PBS 2%FBS.  Bone marrow and blood 
cells were resuspended in 250 ul each PBS 2%FBS.  50 μL aliquots of cells were moved 
to 96 well dish. 1 μL anti-CD16/32 was added to each well to block cells for about 10 
minutes.  One well for each cell type was kept as a no antibody negative control.  Several 
panels of antibodies were designed to assess cell phenotypes present.  Five or six 
different fluorochromes were included in each group, and included FITC (Fluorescein 
Isothiocynate), PE (Phycoerythrin), PE-Cy5 (Phycoerythrin-Cyanine-5), Pe-Cy7 
(Phycoerythrin-Cyanine-7), APC (Allophycocyanin), APC-Cy7 (Allophycocyanin- 
Cyanine-7).  For the APC-Cy7 fluorchrome, I used a streptavidin-conjugated-APC-Cy7  
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secondary to biotin labeled primary antibodies, while the rest of the fluorochromes were 
conjugated directly to the primary antibodies (See Table 5).  Most groups included the 
CD45.1 antibody so that the transplanted cells expressing MLL-AF9 could be gated upon 
for analysis.  Group 1 antibodies included myeloid and bone marrow progenitor markers 
typical of MLL-AF9 myeloid leukemia.  Group 2 antibodies added in some B cell 
markers, while Group 3 included T cell markers, to determine if there was any mixed-
lineage phenotypes present among the leukemic cells.  Group 4 antibodies included 
markers of erythroid, megakaryocyte and NK cell types.  Antibody groups were pre-
mixed then added (approximately 5μl per well) to cells.  Antibodies were incubated with 
cells for 30 minutes on ice in the dark.  Positive and negative compensation beads 
(Becton-Dickinson) were also incubated with antibodies (one well of each fluorochrome 
type or no antibody for negative beads).  Cells were washed one time with 150μl PBS 
2%FBS, then resuspended in 100μl PBS 2%FBS. Secondary streptavidin-APC-Cy7 
conjugate was then added to cells.  Cells were incubated for 30 minutes on ice in the 
dark. Cells were washed two times, then resuspended in a final volume of ~200μl PBS 
2%FBS and moved to FACS tubes.  A FACSCanto flow cytometer (Becton-Dickinson) 
was used to analyze stained cells, and data was analyzed with FlowJo software.  
Table 5.  Fluorochrome-conjugated Antibodies used for Flow Cytometry Analysis of 
Mouse Bone Marrow and Peripheral Blood Cells   
 
FACS FITC PE PE-Cy5 PE-Cy7 APC APC-Cy7 Biotin
Group 1 CD45.1 CD11b Gr-1 CD117 SA Sca-1
Group 2 CD11b CD45.1 B220 Gr-1 CD117 SA CD19
Group 3 PB CD3e CD8a CD4 CD25 CD117 SA CD44
Group 3 BM CD45.1 CD8a CD4 CD25 CD3e SA CD44
Group 4 CD45.1 CD41 TER119 CD117 SA CD49b/DX5
 pos BEADS CD3e CD11b CD4 Gr-1 CD3e SA Sca-1
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RNA Isolation and cDNA Preparation 
 RNA was isolated from week 1 methylcellulose colony assay cells (see above) 
using TRI Reagent (Sigma T9424) according to the manufacturer’s protocol.  cDNA was 
prepared by reverse transcription with the High-Capacity cDNA Reverse Transcription 
Kit (Applied Biosystems #4368814) using random primers. 2μg of RNA was used for 
each sample. For each reaction 2μl of 10X RT Buffer, 0.8μl of 100mM dNTPs, 2μl of 
10X Random Primers, 1μl of MultiScribe Reverse Transcriptase, and nuclease-free H2O 
up to 20μl was used. cDNA was synthesized using following incubation protocol: 10 
minutes at 25°C followed by 120 minutes at 37°C, then 5 seconds at 85°C. cDNA was 
stored at -20°C until further analysis.  No Reverse Transcriptase reactions were also 
performed to ensure that no genomic DNA was present in RNA samples. 
Quantitative RT-PCR 
 Real-time PCR to analyze gene expression using cDNA described above, was 
performed using Taqman kits (Applied Biosystems Master Mix kit #4324018, Hoxa9 kit 
Mm00439364_m1, Hprt kit Mm00446968_m1).  Each sample was analyzed in triplicate 
using 2μL cDNA, 10μL 2X Taqman Master Mix, 1μL 20X Gene Expression Assay 
(Primers/Probe mix), and nuclease free water to 20μL total.  The standard program of one 
cycle of 50°C for 2 minutes, one cycle of 95°C for 10 minutes, 40 cycles of 95°C for 15 
seconds-60°C for 1 minute was run and data was analyzed with ABI Prism 7300.  Primer 
sequences are withheld by Applied Biosystems.  Relative Hoxa9 expression was 
normalized to Hprt expression levels, and calculated using the 2-ΔΔCt method.118  
Experiment was repeated two times. 
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MicroRNA Detection Protocol 
 RNA was isolated from week one colony assay cells using TRI Reagent (Sigma) 
according to the manufacturer’s protocol. Reverse transcription was performed using 
TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems). For the RT step, a 
total of 10ng of RNA was used for each control and testing sample. In a microcentrifuge 
tube 5μL of RNA was mixed with 0.15μL of 100mM dNTPs, 1μL of MultiScribe 
Reverse Transcriptase (50U/μL), 1.5μL of 10X Reverse Transcription Buffer, 0.19μL of 
RNase Inhibitor (20U/μL) and 4.16μL of nuclease-free water. To each control sample 
3μL of the RNU6B RT primer (Applied Biosystems) was added. To each testing sample 
3μL or mir-196b RT primer (Applied Biosystems) was added. The tubes were centrifuged 
briefly and kept on ice for 5 minutes. The tubes were loaded into the PCR Express cycler 
(Hybaid) and the following program was run: 1 cycle of 16°C for 30 minutes, 1 cycle of 
42°C for 30 minutes, 1 cycle of 85°C for 5 minutes, followed by 4°C hold.  
 Real-time PCR was performed using ABI 7300 machine using the standard 
program described above. Each sample was performed in triplicate and contained 10μL 
of TaqMan Universal PCR Master Mix (Applied Biosystems), 7.67μL of nuclease-free 
water and 1.33μL of the RT reaction. To each control sample 1μL of RNU6B 
primer/probe mix was added (Applied Biosystems) and to each testing sample 1μL of 
mir-196b primer/probe mix was added (Applied Biosystems). Relative mir-196b 
expression was normalized to RNU6B levels and calculated using the 2-ΔΔCt method.  
Relja Popovic performed the miR196b Taqman Expression real time PCR experiment 
included in this dissertation. 
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Chromatin Immunoprecipitation Assay 
 The chromatin immunoprecipitation (ChIP) assay was performed using EZ-
Magna ChIP G (Upstate/Millipore, Temecula, CA) according to the manufacture’s 
protocol.  For the CXXC point mutation constructs, Phoenix-Eco cells (Orbigen, San 
Diego, CA) were transfected with MSCV-MLL-AF9-Flag constructs using the CalPhos 
Mammalian Transfection Kit (Clontech, Mountain View, CA).  One dish of transfected 
Phoenix cells (17-25x106 cells) was used for each IP.  70 hours after transfection, cells 
were washed with PBS then trypsinized and moved to falcon tubes.  Cells were 
crosslinked for 10 minutes at room temperature with 37% formaldehyde (final 
concentration 1%). The reaction was quenched with 10X glycine solution for 5 minutes at 
room temperature. Cells were washed with cold PBS twice, then spun down, snap frozen 
and stored at -80°C until ready to proceed.  Cells were thawed on ice, then like cell types 
were combined and resuspended in 1mL SDS Lysis Buffer containing 1X Proteinase 
Inhibitor Cocktail II.  Cells were allowed to lyse for 15 minutes on ice, vortexing every 5 
minutes.  After lysis, cells were spun down and resuspended in nuclear lysis buffer (700-
850μL depending on cell concentration) with 1X Protease Inhibitor Cocktail II.  Lysates 
were sonicated on ice five times 7 seconds at power 4, resting 30-40 seconds between 
cycles, using a Branson Sonifier 250.  After sonication, lysates were centrifuged at 
12,000xg for 10 minutes at 4°C to remove insoluble material.  Supernatants were then 
diluted 10X with Dilution Buffer plus 1X Proteinase Inhibitor Cocktail II and divided up 
into four tubes, for the number of IPs to be done.  1% of each sample was saved as Input 
chromatin.  Before pulldowns, the sampled were pre-cleared to reduce background 
binding of any proteins to the beads.  10μL of magnetic Protein G beads were added to 
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each aliquot and samples were placed on wheel at 4°C for 1 hour.  Samples were then 
placed in the magnetic separator to remove the beads, and lysates were moved to new 
tubes.  20μL fresh magnetic Protein G beads were added to each sample with the 
appropriate antibody.  Chromatin was immunoprecipitated overnight on wheel at 4°C 
using 5μg anti-Flag (Sigma, St. Louis, MO), or 1μg of anti-Histone H3 trimethyl K9 
(Abcam, Cambridge, MA), anti-RNA Polymerase II (Upstate/Millipore) or mouse IgG 
(Upstate/Millipore).  Following incubation, Protein G beads were pelleted with magnetic 
separator and supernatant was removed.  Beads were washed for 5 minutes on ice with 
each solution: low salt buffer, high salt buffer, LiCl buffer and TE buffer.  To elute 
DNA/Protein complexes and reverse crosslinks to free the DNA, beads were resuspended 
in 100 μL ChIP Elution Buffer plus 1 μL Proteinase K.  Samples were incubated at 62°C 
for 2 hours with agitation, then 95°C for 10 minutes.  After allowing the samples to cool 
to room temperature, beads were separated with magnet and supernatants were moved to 
new tubes.  DNA was then purified using spin columns, eluted in 50μL and stored at -
20°C.  Results were analyzed by qPCR as described below.  Enrichment was normalized 
to GAPDH and input chromatin.  Primer sequences for the HOXA9 and GAPDH DNA 
listed in Table 6. 
 For the CXXC domain swap project, ChIP was carried out as described above 
with the following changes.  C-Kit+ mouse bone marrow cells were infected with 
MSCV-MLL-AF9-Flag domain swap retroviral constructs as described above.  Cells 
were harvested and fixed with 1% formaldehyde one week after infection and selection.  
8-10x106 cells were used for Flag IPs and 2-5x106 cells were used for IgG or p16 IPs.  
Lysates were sonicated for six cycles of 10 seconds at power 4.  Results were analyzed 
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by qPCR as described below.  Enrichment of anti-Flag over IgG binding was normalized 
to input chromatin.  Primer sequences for Hoxa9 DNA are listed in Table 6.  
Quantitative PCR for Chromatin Immunoprecipitation Assay 
 For quantitative PCR for Chromatin Immunoprecipitation experiments, DNA was 
analyzed using ABI Prism 7300 sequence detector. Each 25 μL reaction contained 4uL 
ChIP DNA, 12.5μL of 2X iTaq SYBR Green Supermix with Rox (BioRad, Hercules, 
CA) and 0.2 μM forward and reverse primers. All reactions were performed in triplicate 
and DNA levels were detected using SYBR Green reagents. All qPCR reactions were 
performed using the following protocol: one cycle of 50°C for 2 minutes, one cycle of 
95°C for 10 minutes, 40 cycles of 95°C for 15 seconds-60°C for 1 minute, one cycle of 
95°C for 15 seconds-60°C for one minute-95°C for 15 seconds-60°C for 15 seconds.  
DNA levels were normalized to input and fold difference was calculated using 2-∆∆Ct 
method.118  Primers used for Chromatin Immunoprecipitation assays can be found in 
Table 6. 
Table 6.  Primers used for Chromatin Immunoprecipitation Analysis 
 
Amplicon Primers (5’ to 3’) 
HOXA9 AB Region Forward: GAAGCCACTAGTAAGCAAGCAGTC Reverse: GGCTGACTAGGAGATCTGATTAGG 
GAPDH Forward: TACTAGCGGTTTTACGGGCG Reverse: TCGAACAGGAGGAGCAGAGAGCGA 
Hoxa9 AB Region Forward: CGGTGATTTAGGTAGTTTCCTGTTG Reverse:  CACAGCGCCGAGGAAGAC 
 
Nucleofection of Mll -/- MEFs 
 Two million Mll -/- MEF (Stanley Korsemeyer) cells were resuspended in MEF2 
solution (Amaxa) and transfected by electroporation (Amaxa) with no more than 10μg 
DNA in a 5μL volume.  MSCVneo, MSCV-MLL(C1188A)-AF9, or MSCV-
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MLL(C1188D)-AF9 point mutation constructs were co-transfected with a pSuper 
plasmid at a 1:5 molar ratio to confer puromycin resistance.  Program A-23 was used to 
nucleofect the cells with the Amaxa machine, then cells were immediately plated in pre-
warmed (37°C) growth media.  On the second day after transfection, puromycin was 
added to (1.4μg/mL) select for the transfected cells.  After one week of selection, 
genomic DNA was harvested (Puregene DNA kit, Gentra Systems).  If possible, cells 
were cultured out to four weeks post-transfection, and DNA was harvested at week 2 and 
4 timepoints, but only week one data was found to have significance and was fully 
analyzed. 
Bisulfite Sequencing to Measure DNA Methylation 
 2μg DNA from transfected Mll -/- MEFs was subjected to sodium bisulfite 
treatment with the EpiTect Bisulfite Kit (Qiagen).  Conversion was run in PCR machine 
with the following cycling:  5 minutes at 99°C, 25 minutes at 60°C, 5 minutes at 99°C, 85 
minutes at 60°C, 5 minutes at 99°C, 175 minutes at 60°C, then 20°C hold, and was 
followed by DNA cleanup according to the kit.  Nested PCR was performed using 
HotStar Taq(Qiagen) on each sample to amplify the upstream region of Hoxa9 that our 
lab had previously shown to have MLL dependent CpG-DNA methylation protection.  In 
order to PCR amplify bisulfite converted DNA, we must keep in mind that bisulfite 
treatment converts any unmethylated cytosine to uracil, so we assume that a bisulfite 
converted DNA sequence will contain thymines at any position that previously had a 
cytosine that was not within a CpG.  For the cytosines that are part of CpGs, they may or 
may not have been methylated and bisulfite converted.  If a primer crosses a CpG, the 
primers should allow for either a cytosine or thymine at this position in the forward 
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primer, or an adenine or guanine in the reverse primer.  Primers were designed to amplify 
the top strand only of bisulfite converted DNA, and are listed in Table 7.  PCR products 
were sequenced using the same inside primers that were used to ampify the products.  
ImageJ (NIH) software was used to analyze each CpG peak in the sequence tracings.  
Area under the curve values were calculated for each CpG cytosine peak, which 
represents a methylated CpG residue, and its corresponding thymine peak, which 
represents an unmethylated CpG.  Error due to background levels of conversion was 
determined by measuring non-CpG cytosine conversion.  Relative methylation 
percentage at each CpG peak was then calculated.  PCR products were also cloned into 
TOPO vectors (Invitrogen) for sequencing.     
Table 7.  Primers used for Bisulfite Sequencing 
 
Amplicon Primers (5’ to 3’) 
Outside Hoxa9 AB CpGs 
PCR product: 225 bases 
Forward: TTTT(C/T)GTTAGGTTA(C/T)G(C/T)GTTT  
Reverse: AAACAAAACCTCCCTAAAC(A/G)A 
Inside Hoxa9 AB CpGs 
PCR product: 185 bases 
Forward: GTTTTTTGTT(C/T)GT(C/T)GGAGG 
Reverse: AAAAAAC(A/G)CAAAAAACAACAAC 
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CHAPTER 4 
RESULTS 
Aim 1:  Determine if the DNA binding ability of the MLL CXXC domain  
is essential to MLL fusion protein function 
 
Identification of MLL CXXC Point Mutations critical to DNA Binding 
 It was previously shown through deletion studies that the presence of the MLL 
CXXC domain is essential for MLL fusion proteins to confer increased proliferative 
capacity upon transduced bone marrow progenitor cells in in vitro colony assays.  It was 
also demonstrated that point mutations within the CXXC domain that altered the highly 
conserved, zinc-coordinating cysteines or the KFGG motif also disrupted colony 
formation.8  These point mutations were later shown to cause an isolated MLL CXXC 
domain to lose coordination of its two zinc ions, indicating misfolding of the domain.9  
As a misfolded CXXC domain would likely lose all function, these point mutation studies 
did not specifically address whether or not the DNA binding function of the MLL CXXC 
domain is essential to MLL fusion proteins.  In collaboration with our laboratory, John 
Bushweller’s laboratory at the University of Virginia recently solved the structure of the 
MLL CXXC domain and mapped its DNA-binding interface to determine which amino 
acid residues within the domain contact the target DNA (Figure 5A and B).10  The DNA 
used for this structure had a palindromic sequence with a central unmethylated CpG.  
With this information, the Bushweller laboratory introduced point mutations into an 
isolated MLL CXXC domain (amino acids 1147-1203) and measured the resulting
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Figure 5.  Structure of the MLL CXXC domain in complex with DNA and CXXC 
point mutations that disrupt DNA binding 
 
A 
 
 
B 
 
C 
(A) Structure of the MLL CXXC 
domain is shown in green in complex 
with DNA with six central base pairs 
shown in blue. The magenta amino acid 
loop mediates CXXC base specific 
contacts with DNA. Zinc ions are 
shown as black spheres.  (B) MLL 
CXXC in complex with DNA with 
specific amino acids indicated. Green 
residues are involved in electrostatic 
interactions with DNA, the magenta 
Q1187 forms a hydrogen bond with the 
guanine base of the CpG, and C1188 in 
yellow is in close proximity to the 
DNA.  (C) Relative dissociation 
constants (Kd) for binding of isolated 
wild type or mutant MLL CXXC to 
unmethylated CpG DNA. The Kd for 
the C1188D mutant could not be 
determined due to very weak binding. 
Figures were provided by the 
Bushweller Laboratory. 
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changes in binding affinity by NMR titration to the nonmethylated CpG-containing target 
DNA molecule for each CXXC point mutant (Figure 5C).  They also used NMR to 
determine that each introduced point mutation did not cause the domain to undergo any 
structural changes as compared to the unmutated MLL CXXC domain.   
 The MLL CXXC point mutations that we decided to pursue for further functional 
studies were R1154A, K1185A, Q1187A, C1188D, and C1188A.  The R1154A and 
K1185A mutations disrupt electrostatic interactions between their amino acid side chains 
and the sugar phosphate backbone of the target DNA.  These mutations decrease CXXC 
binding affinity by 10.5 and 14.6 fold, respectively.  Lysine1185 also contributes a 
hydrogen bond interaction between the carbonyl group of the lysine amino acid protein 
backbone with the amine group of the CpG cytosine; however, mutation of this residue to 
alanine or any other amino acid would not disrupt this interaction as it does not involve 
the specific amino acid side chain.  The Q1187A mutation disrupts a CXXC side chain 
hydrogen bond interaction with the guanine base of the CpG residue, which decreases the 
binding affinity by 6.4 fold.  Cysteine1188 is not involved in any DNA contacts; 
however, it is in close proximity to the DNA.  We hypothesized that mutation of this 
residue to the negatively charged amino acid aspartate could introduce a repulsive 
interaction between the CXXC domain and the DNA.  When the C1188D mutation was 
introduced into the MLL CXXC domain, DNA binding was completely abolished.  At the 
same amino acid, a C1188A mutation has no negative effect on CXXC binding to DNA 
(Figure 5C).10  In order to determine if DNA binding is a property of the MLL CXXC 
domain that is essential to MLL fusion proteins in their ability to promote leukemia, I 
introduced the above mutations into the CXXC domain of an MLL-AF9 fusion protein. 
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Cloning of MLL CXXC Point Mutations into MSCV-MLL-AF9-Flag 
 As MLL-AF9 cDNA is quite long, it is not practical to perform site-directed 
mutagenesis to introduce mutations, as the entire 4.4 kilobase coding region plus 6.5 
kilobase vector construct would need to be sequenced following PCR.  Mutations had 
also already been introduced into isolated MLL CXXC domains in pGex bacterial 
expression vectors by the Bushweller Laboratory.  In order to efficiently introduce the 
point mutations into MLL-AF9, two restriction enzymes were utilized that could cut at 
either end of the approximately 150 nucleotide (50 amino acid) CXXC domain.  MLL 
contains an endogenous AatII restriction site at the 5’ start of the CXXC domain which 
corresponds to MLL amino acid 1149.  To cut at the 3’ end of the CXXC domain, I 
created a BamHI restriction site at the DNA site corresponding to MLL amino acid 1201, 
and destroyed an endogenous BamHI site at MLL amino acid 1250.  Introduction of the 
BamHI site inserted a glycine residue into the MLL amino acid sequence carboxy-
terminal to the CXXC domain.  As this glycine appears in the unstructured region of the 
CXXC domain, it was not expected to alter the function of MLL or MLL-AF9.  I later 
performed side-by-side colony assays to compare the transformation potential of the 
altered MLL-AF9 with an unmutated MLL-AF9 and determined that there was no 
difference.  I next PCR amplified the point mutation-containing CXXC domains, and 
digested the products with AatII and BamHI to swap them into the 4.1 kilobase 5’ MLL 
fragment that is retained in leukemic MLL fusions.  After sequencing the regions that had 
been PCR amplified and digested, I performed three-way ligations to create CXXC point 
mutation containing-MSCV-MLL-AF9-Flag constructs. 
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Retrovirus Production and Titers 
 In order to stably express MSCV-MLL-AF9 constructs in primary murine bone 
marrow cells, retroviruses containing the constructs were used to infect the cells.  This 
retroviral transduction causes the MSCV-MLL-AF9 DNA to be integrated into the 
genome of the cells.  Ecotropic Phoenix cells, which were engineered with retroviral 
packaging genes and were derived from the human embryonic kidney (HEK 293) cell 
line, were employed to produce retrovirus.  I used calcium phosphate to transfect 
MSCVneo (empty vector), MSCV-MLL-AF9-Flag, or MSCV-MLL (CXXC point 
mutations)-AF9-Flag constructs into Phoenix-Eco cells, and collected and concentrated 
the retrovirus that was produced.  The transfected Phoenix-Eco cells were also saved to 
perform Western Blots to confirm stable protein expression of the mutant MLL-AF9 
constructs.  To ensure that the viruses collected were of sufficient concentration to infect 
primary bone marrow cells, I performed retroviral titering using Rat1A cells.  Ideal titers 
were in the 1x105 to 10x106 virus particles/mL range, but titers as low as 5x104 
particles/mL were acceptable if larger volumes of virus supernatant were used for 
infection (Figure 6A). 
Confirmation of Stable Expression of MLL-AF9-Flag CXXC Mutant Proteins 
 While the Bushweller laboratory had shown that the CXXC point mutations did 
not disrupt folding or expression of the isolated MLL CXXC domain in vitro, it was also  
important to show that introduction of the point mutations did not disrupt the stability or  
expression of an MLL-AF9 fusion protein in cells.  Protein lysates were obtained from 
 
Phoenix cells which had been transfected with MSCVneo, MSCV-MLL-AF9-Flag, or 
MSCV-MLL-AF9-Flag with CXXC point mutations.  Anti-Flag agarose beads were used  
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Figure 6.  Retroviral Titering and Expression of MLL-AF9 CXXC Point Mutation 
Proteins  
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(A) Methylene blue stains of retrovirally infected Rat1A cells after 10 days of G418 
selection, with virus dilutions indicated.  (B)Detection of MSCV-MLL-AF9-Flag or 
CXXC point mutation constructs in transfected or untransfected Phoenix cell lysates 
subjected to immunprecipitation and western blotting with anti-Flag antibody. 
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to concentrate the Flag-tagged MLL-AF9 proteins, and an anti-Flag antibody was used to 
detect the fusion proteins by Western Blot.  The absolute level of expression was not 
important, as expression in the bone marrow cells would depend on virus titer used to 
infect the cells and the sites of genomic integration of the DNA in individual cells.  
Instead it was important to see that the proteins were all present and at the expected size 
on the blot, which indicates that there is no degradation of the proteins or any previously 
undetected cloning mistakes (Figure 6B). 
MLL CXXC point mutations that disrupt DNA binding reduce the  
transformation potential of MLL-AF9 in bone marrow colony assays 
 
 When cultured in semi-solid methylcellulose media containing the appropriate 
cytokines, normal bone marrow progenitor cells will form colonies in the first week of 
plating, then undergo differentiation and die within a couple of weeks.  Bone marrow 
progenitor cells that express MLL fusion proteins, however, have enhanced proliferation 
and are able to be serially replated in methylcellulose colony assays.  In order to 
determine if the DNA binding function of the MLL CXXC domain is critical for MLL-
AF9 to confer an enhanced proliferative capacity to bone marrow progenitor cells, I 
performed in vitro colony assays.  I hypothesized that the MLL CXXC DNA binding 
function is critical to MLL-AF9 function, so I expected that those point mutations that 
conferred reduced DNA binding ability in the isolated MLL CXXC domain binding 
assays would cause reduced colony formation ability in the context of MLL-AF9.   
 C-Kit+ bone marrow progenitor cells were isolated from mice then were infected 
by spinoculation with retroviral particles containing MSCVneo, MSCVneo-MLL-AF9-
Flag or MSCVneo-MLL-AF9-Flag with R1154A, K1185A, Q1187A, C1188D, or 
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C1188A CXXC point mutations.  Transduced bone marrow cells were then plated in 
methylcellulose with cytokines IL-6, IL-3, GM-CSF and SCF.  For the first week of 
plating, the transduced cells were selected for survival with geneticin (G418), as the 
MSCVneo vector contains a neomycin resistance cassette.  After each week, colonies and 
cells were counted and were replated if colonies were present and cell numbers were 
sufficiently high.  MLL-AF9-expressing bone marrow cells are highly proliferative, and 
colony formation can be limited by the nutrients and amount of methylcellulose available 
in individual dishes.  Therefore, while the non-transforming constructs were plated at 
10,000 cells per dish, after the initial week of selection, MLL-AF9 and any other highly 
transforming constructs were plated at concentrations of 1,000 to 3,000 cells per dish, 
then the resulting colony and cell numbers were normalized for comparison to the 
constructs that had 10,000 cells plated.  Colony assays were all performed in duplicate 
and were repeated at least six times.  Results are presented as averages of all colony 
assays in which at least 10 colonies were present at the end of the first week of selection.  
Colony assay results often vary from experiment to experiment, due to differences in 
viral titers used to infect the cells, the specific state of differentiation of the cells that had 
been infected, and the locations of genomic integration of the constructs which can confer 
high or low expression.   
 As seen in Figure 7A, MLL-AF9 expressing bone marrow cells produced 1500 
colonies on average during week four of the colony assay, which was a statistically 
significant increase as compared to MSCVneo cells.  Almost 16% of the MLL-AF9 
plated cells gave rise to a colony, and the total cell numbers increased on average by 900 
to 1000-fold each week.  MLL CXXC point mutation C1188A did not perturb DNA 
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binding activity of the isolated CXXC domain.  MSCV-MLL(C1188A)-AF9 expressing 
bone marrow cells produced many colonies and showed no statistical difference to the 
unmutated MLL-AF9, as expected.  Both constructs produced large, round, densely 
packed colonies typical of bone marrow progenitor cells (Figure 7B).  At the end of the 
fourth week of replating, cells were taken for morphological analysis.  Cytospins of the 
cells onto slides were performed, followed by staining with Hema-3, a Wright-Giemsa-
like stain.  Digital pictures of the cells indicated the MLL-AF9 and MLL(C1188A)-AF9 
colony assay cells had a blast-like morphology, with large nuclei and little cytoplasm.  
Cells taken from week 4 of the colony assay were stained with a panel of antibodies 
directed against a variety of mouse hematopoietic cell surface markers in order to 
determine the phenotype of the cells.  MLL-AF9 and MLL(C1188A)-AF9 cells co-
expressed myeloid markers CD11b and Gr-1, and expressed c-Kit at a low level (Figure 
8).  These cells also expressed B-cell marker CD19, but had very low expression of the 
erythroid cell marker TER119 and T-cell marker CD3e. 
 Point mutations that caused reduced binding of the isolated CXXC domain to 
DNA also significantly reduced MLL-AF9 colony forming ability.  The number of 
colonies produced by MLL-AF9 with point mutants R1154A, K1185A, and Q1187A, 
which reduced MLL CXXC binding to DNA by 10.5, 14.6, and 6.4 fold, respectively, in 
the final week of the assay varied, and ranged from zero up to 300.  However, compared 
to unmutated MLL-AF9, all three mutants showed statistically significant decreases in 
clonogenic activity.  The morphologies of these point mutant colonies differed 
significantly from those of MLL-AF9 and were more typical of differentiated bone 
marrow cells (Figure 7B).  The colonies were most often less dense and smaller than the  
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Figure 7.  MLL-AF9 CXXC Point Mutation Bone Marrow Colony Assay 
 
A 
 
B 
 
 
(A) Average numbers of colonies for weeks two through four after re-plating in methyl-
cellulose are shown for bone marrow progenitor cells expressing MLL-AF9 or MLL-AF9 
with indicated CXXC domain point mutations, with error bars showing standard error. 
Relative Kd values for binding of the wild type and mutated MLL CXXC domains to 
DNA are also shown.  (B) Digital photographs showing colony (above) and cell (below) 
morphologies of transduced bone marrow cells at the end of week 4 of the colony assay.   
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MLL-AF9 colonies (Figure 7B), although they did show some variability.  As compared 
to MSCVneo colony numbers, MLL-AF9 with point mutations R1154A and K1185A, 
but not Q1187A, showed a small but statistically significant increase in average colony 
number.  The proliferative capacity of these point mutant-transduced cells was also 
greatly diminished, with total cell numbers increasing on average ten-fold less than with 
MLL-AF9.  Surviving week 3 or 4 colony assay cells expressing MLL-AF9 with point 
mutations R1154A, K1185A, or Q1187A showed a different phenotype than the MLL-
AF9 cells, as seen by flow cytometry analysis.  While CD11b and Gr-1 remained high, 
these cells showed increased expression of TER119 and decreased expression of CD117 
as compared to the MLL-AF9 cells (Figure 8). 
 Point mutation C1188D, which completely abolished detectable DNA binding in 
the isolated MLL CXXC domain, showed the most severe phenotype in the colony 
assays.  The MLL(C1188D)-AF9 transduced bone marrow cells lacked colony forming 
ability and showed no statistically significant difference in week 4 colony numbers as 
compared  to the MSCVneo negative control  (Figure 7A). The C1188D mutant cells 
proliferated on average only 1.7 fold, and colonies rarely survived into the fourth week of 
the colony assay.  The surviving colonies were always very diffuse with small numbers 
of differentiated cells (Figure 7B).  Immunostaining of week 3 colony assay 
MLL(C1188D)-AF9-expressing cells revealed lower levels of Gr-1 and CD11b as 
compared to the MLL-AF9 cells, but very high levels of c-Kit, which is typical of 
differentiated mast cells (Figure 8).  Overall, the colony assay results show a high 
correlation with the DNA binding affinities of the isolated point mutation-containing 
MLL CXXC domains (Figure 7A).  From these colony assays, we concluded that the 
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Figure 8. FACS Profiles of MLL-AF9 CXXC Point Mutation Bone Marrow Colony 
Assay Cells 
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Bone marrow cells taken from week 3 or 4 of the colony assay, expressing the indicated 
MLL-AF9 CXXC point mutation constructs, were analyzed by flow cytometry using 
fluorochrome-conjugated antibodies directed against CD11b, CD3e, TER119, Gr-1, 
CD117, and CD19. 
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DNA binding function of the MLL CXXC domain is critical for MLL-AF9 to confer 
enhanced proliferative capacity upon murine bone marrow progenitor cells in vitro. 
MLL CXXC point mutations that disrupt DNA binding abolish the ability  
of MLL-AF9 to promote leukemia in vivo 
 
 In order to determine if the DNA binding function of the MLL CXXC domain is 
critical for an MLL-AF9 fusion protein to cause leukemia in vivo, mouse leukemia assays 
were performed.  As previously described,119 c-Kit positive murine bone marrow 
progenitor cells were isolated from CD45.1+ B6.SJL donor mice and were retrovirally 
transduced with MSCVneo, MSCV-MLL-AF9-Flag, MSCV-MLL(C1188A)-AF9-Flag, 
or MSCV-MLL(C1188D)-AF9-Flag.  Along with whole bone marrow cells for 
radioprotection, the transduced cells were transplanted into lethally irradiated C57Bl/6 
recipient mice.  As the bone marrow cells from the recipient mice do not express CD45.1, 
this cell surface marker could be used to track those transplanted bone marrow cells that 
had received the retrovirus transductions.  The mice were observed several times per 
week, and blood samples were taken periodically (every 2-6 weeks).  Complete blood 
counts were analyzed using a Hemavet (Drew Scientific, Oxford, CT), and flow 
cytometry using an anti-CD45.1 antibody was used to monitor expansion of the donor 
bone marrow cells in the peripheral blood of the mice.  Mice were sacrificed when they 
started to become moribund.  Sick mice were often underweight, with ruffled fur and 
slow mobility, and had elevated white blood cell counts.   
 As seen in Figure 9A, similar to the MSCV-MLL-AF9 mice, all of the MSCV-
MLL(C1188A)-AF9 mice developed leukemia.  In this experiment, the disease in the 
MLL(C1188A)-AF9 mutant mice (n = 8) progressed at an even faster rate than the MLL-
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AF9 mice (n = 3), with average latencies of 39.5 days and 94 days, respectively.  
However, similar to the MSCVneo mice (n = 5), none of the MSCV-MLL(C1188D)-AF9 
mice (n = 9) developed leukemia during the course of the experiment, which extended for 
200 days.  Peripheral blood and bone marrow smears indicated an increased percentage 
of blast cells in the MSCV-MLL(C1188A)-AF9 leukemic mice (Figure 9B and C).  
Median complete blood cell counts at the time of sacrifice was 23.9 K per μL for the 
MSCV-MLL(C1188A)-AF9 mice and 18 K per μL for the MLL-AF9 mice.  The normal 
whole blood count for healthy mice ranges from 1.8 - 10.7 K cells per μL.  The sick mice 
often had enlarged spleens and livers, pale femurs, and infiltrates in multiple organs.  The 
weight of the spleens from the MSCV-MLL(C1188A)-AF9 mice averaged 8 times that of 
the healthy MSCV-MLL(C1188D)-AF9 mice at time of sacrifice.  Organs including 
spleen, liver, lungs, heart, kidneys and thymus from all sick and some healthy mice for 
comparison, were fixed in formalin and processed by the histology core facility at Loyola 
University Medical Center for hematoxylin and eosin (H&E) staining.  The livers, lungs 
and spleens of the leukemic mice typically showed infiltration of leukemic cells (Figure 
9C).  Peripheral blood and bone marrow cells from the leukemic mice were stained with a 
panel of antibodies directed against a variety of mouse hematopoietic cell surface 
markers in order to determine the phenotype of the leukemia cells.  An anti-CD45.1 
antibody was included in the antibody mix so that the cells expressing MLL-AF9 or 
MLL(C1188A)-AF9 could be gated upon during data analysis.  The leukemic cells 
expressed high levels of myeloid markers CD11b and Gr-1, moderate levels of the 
progenitor cell marker c-Kit, and were negative for T-cell marker CD3e and B-cell 
marker B220 (data not shown).  
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Figure 9. In vivo MLL-AF9 CXXC Point Mutation Leukemia Assay 
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(A) Survival curve of mice transplanted 
with bone marrow progenitor cells infected 
with MSCVneo, MSCVneo-MLL-AF9, 
MSCVneo-MLL(C1188A)-AF9, or 
MSCVneo-MLL(C1188D)-AF9(C1188D). 
Numbers of mice per group are indicated.  
(B) Peripheral blood from mice at time of 
sacrifice (MLL(C1188A)-AF9) or at two 
months after bone marrow transplants 
(MSCVneo and MLL(C1188D)-AF9).   
(C) Hematoxylin- and eosin-stained 
sections of liver, lung and spleen or bone 
marrow smears from an MLL-AF9 
(C1188A) mouse (at time of sacrifice) or a 
healthy MSCVneo mouse two months after 
bone marrow transplant.   
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MLL CXXC DNA binding activity is essential for MLL fusion proteins to protect 
target Hoxa9 CpG DNA from methylation in Mll-/- mouse embryonic fibroblasts 
  
 Our laboratory previously discovered that the DNA methylation status of a cluster 
of CpGs in a CpG island upstream of the AB exon of Hoxa9 is MLL dependent.6  Using 
Mll null mouse embryonic fibroblasts (MEFs), we showed that this cluster of eight CpG 
residues has high levels of DNA methylation when Mll is absent, but when MLL is added 
back to the cells, DNA methylation levels decrease.  When the MLL fusion protein MLL-
AF4 was added back to the Mll-/- MEFs, DNA methylation of the first five of the eight 
CpGs in the cluster was reduced.6  We hypothesized that this DNA methylation 
protection function of MLL is facilitated by the MLL CXXC domain as it is known to 
bind to unmethylated CpGs.  To test this hypothesis, I transfected the MSCVneo, MSCV-
MLL(C1188A)-AF9-Flag, or MSCV-MLL(C1188D)-AF9-Flag constructs into the Mll-/- 
MEFs.  I expected that the MSCV-MLL(C1188A)-AF9 construct would confer reduced 
levels of DNA methylation on the cluster of CpGs in the upstream region of Hoxa9, 
while in MSCVneo and MSCV-MLL(C1188D)-AF9 transfected cells, DNA methylation 
levels would remain high at this cluster.  As the Mll-/- MEFs are resistant to transfection, 
the Amaxa nucleofection technique was used to transfect the MSCV-MLL-AF9 point 
mutant constructs along with a pSuper vector.  The Mll-/- MEFs were engineered with a 
neomycin resistance cassette, so the pSuper vector was included so that puromycin could 
be used to select for the cells into which the plasmids were successfully introduced.    
 After one week of antibiotic selection, genomic DNA was isolated from the cells 
and was treated with sodium bisulfite, which converts any unmethylated cytosines to 
thymines.  The upstream region of Hoxa9 was then amplified by PCR using primers that 
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had been designed to amplify sodium bisulfite converted DNA.  Two successive PCR 
reactions using nested primers were needed to generate sufficient PCR products for 
analysis, as bisulfite treatment can be harsh on DNA integrity.  PCR products were 
sequenced directly in order to get an accurate average percentage of DNA methylation 
from the whole population of cells from which the genomic DNA was harvested.  
Relative levels of DNA methylation were calculated for each CpG in the upstream Hoxa9 
cluster.  As seen in Figure 10, MEFs transfected with MSCVneo or MLL(C1188D)-AF9, 
which does not have CXXC DNA binding activity, show higher levels of DNA 
methylation at all CpGs previously shown to be protected from methylation by MLL.  
This was measured as compared to the cells transfected with MLL(C1188A)-AF9, which 
has normal CXXC DNA binding activity.  The first five of the eight CpGs show 
increased protection from methylation by MLL(C1188A)-AF9, as was observed in our 
earlier studies using the MLL-AF4 fusion protein.  This experiment was repeated three 
times, with one representative experiment shown.  These results confirmed our 
hypothesis that the DNA binding activity of the MLL CXXC domain is critical to the 
MLL function of protecting Hoxa9 from DNA methylation. 
MLL CXXC DNA binding activity is essential for MLL fusion proteins to promote 
overexpression of Hoxa9 and miR196b in bone marrow progenitor cells 
 
 The presence of unmethylated CpG islands in the promoters of genes is often 
correlated with active gene expression.  As MLL CXXC DNA binding is necessary to  
keep CpGs in the MLL target gene Hoxa9 in the unmethylated state, we hypothesized 
that it is also necessary to promote expression of Hoxa9.  RNA was isolated from week 
one murine bone marrow colony assay cells expressing MLL(C1188A)-AF9 or  
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Figure 10.  Hoxa9 DNA Methylation Levels in MLL(C1188A)-AF9 and 
MLL(C1188D)-AF9-expressing Mll-/- Mouse Embryonic Fibroblasts 
 
 
 
 
 
Relative methylation levels of CpGs in the upstream Hoxa9 locus in Mll null MEFs 
transfected with either MSCVneo-MLL-AF9(C1188A) or MSCVneo-MLL-
AF9(C1188D) and pSuper, after one week of puromycin selection.  Bisulfite treatment, 
PCR and sequencing on genomic DNA samples were performed three times, and the 
results of one representative experiment are shown.   
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MLL(C1188D)-AF9 (as described above).  RNA was converted to cDNA, then was 
assayed for Hoxa9 and miR196b expression using Taqman probes in a real-time RT-PCR 
assay (performed by Relja Popovic).  MiR196b is a microRNA that arises from the 
upstream AB exon of Hoxa9, and like Hoxa9, is overexpressed in MLL leukemias.120  As 
seen in Figure 11A and B, bone marrow cells expressing MLL(C1188A)-AF9 show high 
levels of  Hoxa9 and miR196b, as would be expected for an MLL fusion protein.  
However, the CXXC DNA binding-deficient MLL(C1188D)-AF9, similar to MSCVneo, 
is not able to promote overexpression of these Hoxa9 transcripts.  This suggests that the 
CXXC binding activity is critical to the function of an MLL fusion protein to overexpress 
Hoxa9.    
MLL CXXC DNA binding activity is not critical for MLL fusion proteins  
to localize to the Hoxa9 Locus 
 
 We have established the importance of the DNA binding function of the MLL 
CXXC domain to MLL fusions in promoting leukemia, protecting Hoxa9 DNA from 
becoming methylated, and in promoting expression of Hoxa9.  It remains to be addressed 
if the DNA binding function of the MLL CXXC domain is critical for MLL fusion 
proteins in their localization to target genes such as Hoxa9.  While the CXXC domain is 
one of only two known DNA binding domains within MLL, the CXXC domain centers 
its binding on only one CpG motif at a time, indicating a lack of sequence specificity 
beyond the unmethylated CpG.10  However, as the MLL(C1188D)-AF9 protein was  
unable to activate Hoxa9, I expected that this could be due to loss of localization of  
 
MLL(C1188D)-AF9 to the Hoxa9 locus.  I performed chromatin immunoprecipitation  
 
(ChIP) assays in transfected Phoenix-Eco (human) cells to test for binding of  
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Figure 11.  Hoxa9 expression and fusion protein chromatin localization in 
MLL(C1188A)-AF9 and MLL(C1188D)-AF9-transduced bone marrow progenitors 
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Expression levels of Hoxa9 (A) and mir196b (B) in bone marrow progenitor cells 
transduced with MSCVneo vector, MLL-AF9(C1188A), or MLL-AF9(C1188D). Cells 
were harvested after one week culture in methylcellulose and expression levels of Hoxa9 
and mir196b were quantified with real-time RT-PCR.  Shown are average relative 
expression levels, with error bars indicating standard deviation.  Relja Popovic provided 
graphs shown in A and B. (C) ChIP assay performed on Phoenix cells transfected with 
FLAG tagged MSCV-MLL-AF9(C1188A) or MSCV-MLL-AF9(C1188D).  Chromatin 
was immunoprecipitated with the indicated antibodies and real time PCR was performed 
with primers that localize near mir-196b in the upstream region of the HOXA9 locus.  
Samples were run in triplicate and were normalized to GAPDH and input chromatin, with 
error bars showing range. 
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MLL-AF9(C1188D) and MLL-AF9(C1188A) to the upstream AB exon of HOXA9.  
Immunoprecipitations were performed with anti-Flag antibody for the mutant MLL-AF9 
proteins, IgG as a negative control, anti-RNA Polymerase II as a mark of active 
transcription, and anti-H3K9-trimethylated as a mark of repressed transcription.  Real-
time PCR followed the pulldowns to determine the enrichment of the proteins or 
chromatin modifications at the upstream AB exon of HOXA9.  Surprisingly, my results 
showed no significant difference in the binding of the MLL(C1188A)-AF9 and 
MLL(C1188D)-AF9 proteins to HOXA9 (Figure 11C).  RNA Polymerase II showed a 
small but insignificant decrease in the MLL(C1188D)-AF9 cells; the presence of 
Polymerase II could indicate a paused state of transcription in these cells.  The repressive 
trimethyl-H3K9 mark, however, did show a significant increase in the MLL(C1188D)-
AF9 cells compared to the MLL(C1188A)-AF9 cells.  Two independent ChIP 
experiments were performed, with similar results seen.   
 The results indicate that while the CXXC binding deficient MLL(C1188D)-AF9 
protein can  still localize to HOXA9, the target gene remains in an inactive, repressed 
state.  We concluded that the DNA binding function of the MLL CXXC domain is not 
absolutely critical for localization of MLL fusion proteins to target genes.  Instead, we 
expect DNA interactions through the MLL AT hooks, and perhaps interactions with 
proteins such as Menin and LEDGF which also bind to DNA, to be important for MLL 
target localization.   
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Aim 2: Determine whether CpG DNA binding domains from other proteins can 
substitute for the MLL CXXC domain within the context of MLL-AF9 
 
Cloning, Bacterial Expression and Protein Purification of CpG-Binding Domains  
in GST-Fusion Constructs 
 
 Several individual isolated CXXC and MBD domains have been previously tested 
for DNA binding ability and specificity.  However, the affinities of these CpG-binding 
domains to the same target DNA molecule have never been measured in a side by side 
experiment; doing so would allow the DNA binding affinities of the domains to be  
directly compared to each other.  We chose to study the MLL CXXC, CGBP CXXC, 
DNMT1 CXXC, MBD1 CXXC and MBD1 MBD domains (Figure 12A).  Previous work 
by us and others has shown that the MLL CXXC domain preferentially binds to  
unmethylated CpG DNA.8-10, 117  The CGBP CXXC domain, from the co-activator CpG-
Binding Domain Protein (CGBP/Cfp1/CXXC1), is also known to bind to unmethylated 
CpG DNA,121 so was expected to bind with similar affinity to the target DNA as MLL 
CXXC.  The DNMT1 DNA maintenance methyltransferase protein provides enzymatic 
DNA methylation activity on hemi-methylated DNA substrates.109  Its CXXC domain 
was recently shown to interact with unmethylated DNA in an auto-inhibitory manner in 
order to protect any unmethylated DNA that is encountered by DNMT1 from its 
enzymatic activity.96  Therefore, the DNMT1 CXXC domain was also expected to be 
able to bind to the nonmethylated DNA probe.  From the repressor protein Methyl-
Binding Domain Protein-1 (MBD1), the MBD domain preferentially binds to methylated 
DNA,93 acting opposite to most CXXC domains.  The MBD1 protein contains either two 
or three CXXC domains depending on the splice variant (Figure 4C).  We chose to study 
the MBD1 CXXC domain with the least amino acid similarity to MLL CXXC (Figure  
73 
Figure 12.  Alignment of CXXC domains and Expression of CXXC-GST or MBD-
GST fusion proteins   
 
 
 
A 
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(A) CXXC domains are aligned to show amino acid sequence conservation: those 
identical in all, or present in two or more are shaded in dark and light grey, respectively.  
Sequence of the MBD1 MBD is also shown.  (B) Digital photographs of Coomassie Blue 
stained SDS-PAGE gels of CXXC-GST fusion proteins in fractions eluted from GST 
beads following purification. 
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12A).  It was previously shown that the Mbd1 mouse isoform of this CXXC domain is 
unable to bind DNA regardless of methylation status.111  We expected that neither the 
MBD nor the CXXC domain from MBD1 would be able to bind to the unmethylated 
CpG DNA probe with a sequence derived from an MLL binding site in Hoxa9.6 
 The MLL CXXC domain (amino acids 1147-1203) in pGEX-4T2 was provided 
by the Bushweller laboratory and is the same construct that was used to solve the 
structure of the domain.  I cloned the isolated DNMT1 CXXC, CGBP CXXC, MBD1 
CXXC, and MBD1 MBD domains into pGEX-4T1.  I included 57 amino acids from the 
CXXC domains, as was used for MLL CXXC, and 75 amino acids for the MBD1 MBD 
domain as was used to solve the structure of this domain92 (Figure 12A).  pGEX vectors 
produce GST-tagged fusion proteins and allow for inducible expression in bacteria for 
large-scale protein purification.  After cloning, the constructs were sequenced and 
expressed in bacteria on a small scale to verify GST-tagged protein expression.  The 
proteins were then expressed in BL21 bacteria cells on a large scale, and were purified 
using glutathione agarose affinity chromatography.  Purified proteins were analyzed by 
SDS-PAGE (Figure 12B).   
MLL CXXC domain binds with a higher affinity to unmethylated CpG DNA  
than other CXXC and MBD domains tested 
 
 Binding affinity was measured by fluorescence polarization to a fluorescein-
labeled DNA probe with a sequence derived from an MLL binding site in Hoxa9.6  This 
DNA probe has two central nonmethylated CpGs.  After I expressed the proteins and 
shipped them to Virginia, Aravinda Kuntimaddi (University of Virginia) performed the 
fluorescence polarization experiment presented here.  The experiment was repeated three 
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times, with one representative experiment shown.  Increasing concentrations of the 
proteins were added to a constant amount of DNA until saturation of binding was 
approached.  This allowed us to generate curves (Figure 13A) that we used to calculate 
absolute and relative binding affinites (Figure 13B).  The MLL CXXC domain has the 
highest DNA binding affinity of the domains tested, at 0.64 μM, to the unmethylated 
target DNA, and its relative binding affinity was set to 1.  CGBP CXXC domain has the 
second highest DNA binding affinity at 4.44 μM, or about 7-fold lower than the MLL 
CXXC.  The DNMT CXXC domain came in third with a binding affinity of 21.9 μM, or 
34-fold lower binding than MLL CXXC.  As expected, neither MBD1 CXXC nor MBD1 
MBD is able to bind to the unmethylated DNA.  In conclusion, while most of the CXXC 
domains are able to bind to the unmethylated CpG-containing DNA, there are significant 
differences in the DNA binding affinities measured.   
Cloning of alternate CXXC or MBD domains in the place of the MLL CXXC 
domain into MSCV-MLL-AF9-Flag Constructs 
 
 Domain swap experiments are those in which a functional protein domain from a 
one protein is removed and replaced with a similar or different type of domain from a 
different protein.  Functional experiments can be performed on the domain swapped 
proteins to give insight into function and level of specificity and uniqueness of a 
particular protein domain to its protein.  Determination of common features among 
similar domains from alternative proteins can also be assessed in order to more fully 
understand a protein domain and perhaps its evolutionary history. 
 To swap in alternate CpG-Binding domains in place of the MLL CXXC domain 
in MLL-AF9, the pMCS5-5’MLL construct with the BamHI site moved from amino acid  
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Figure 13.  Relative binding affinities of isolated CXXC domains to unmethylated 
CpG-containing DNA    
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(A) Representative binding curves for fluorescein labeled DNA titrated with increasing 
concentrations of GST-tagged CXXC domains and measured by fluorescence 
polarization. (B) Absolute and relative Kd values for each of the GST-tagged CXXC 
domains. Absolute Kd values were determined from the fluorescence polarization titration 
curves. Relative Kd values were determined by comparison to GST-MLL CXXC (set to 
1).  Figures were provided by Aravinda Kuntimaddi, University of Virginia. 
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1250 to 1201 was employed, as was described above.  The AatII and BamHI restriction 
sites were again used to swap in the CXXC or MBD domains into 5’ MLL.  The CGBP 
CXXC (CGBP amino acids 163-215), DNMT1 CXXC (DNMT1 amino acids 649-697), 
MBD1 CXXC (MBD1 amino acids 172-221) and MBD1 MBD (MBD1 amino acids 1-
75) were PCR amplified, using primers to add the AatII and BamHI restriction sites onto 
the ends of the domains.  The domains were amplified to insert a similar number of 
amino acids into MLL as were taken out with the MLL CXXC domain by digesting 
5’MLL with AatII at amino acid site 1149 and BamHI site 1201.  After swapping in the 
alternate domains and sequencing, three way ligations were performed to create 
MSCVneo-MLL-AF9-Flag CXXC domain swap constructs (Figure 14A).    
Retrovirus Production and Titers and Confirmation of Stable Expression of  
MLL-AF9-Flag CXXC Domain Swap Proteins 
 
 MSCV-MLL(MLL CXXC)-AF9-Flag, MSCV-MLL(CGBP CXXC)-AF9-Flag, 
MSCV-MLL(DNMT1 CXXC)-AF9-Flag, MSCV-MLL(MBD1 CXXC)-AF9-Flag, 
MSCV-MLL(MBD1 MBD)-AF9-Flag, and MSCVneo DNA constructs were used to 
transfect Phoenix-Eco cells and produce and titer retrovirus as previously described in the 
point mutation section (Figure 14B).  The same Phoenix-Eco cells were collected and 
assayed for MLL fusion protein expression by Immunoprecipitation and Western Blot 
analysis with anti-Flag antibody, also as described previously.  All domain swap 
constructs produced MLL fusion proteins of similar molecular weight (Figure 14C), 
suggesting there were no problems with the cloning of the constructs or stability of the 
mutant proteins.  In some cases, two bands were observed (Figure 14C), with the lower  
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Figure 14.  Schematic and Expression of MLL-AF9 CXXC Domain Swap Proteins 
 
 
 
A 
 
B 
 
(A) Schematic of CXXC domain 
swaps into MLL-AF9-Flag.   
(B) Methylene blue stains of 
retrovirally infected Rat1A cells 
after 10 days of G418 selection, 
with virus dilutions indicated.   
(C) Western blots of MLL-AF9-
Flag proteins with indicated CXXC 
domain swaps from transfected 
Phoenix-Eco cells. Fusion proteins 
were immunoprecipitated and 
blotted with anti-Flag antibody.  
Upper bands represent the fusion 
proteins, while the lower bands are 
degradation products. 
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mobility band corresponding to the full length MLL-AF9 fusion protein, and the smaller 
band likely a degradation product. 
DNMT1 CXXC domain can functionally replace the MLL CXXC domain in an 
MLL fusion protein in an in vitro immortalization assay 
 
 In order to determine if the alternate CpG binding domains can function in the 
place of the MLL CXXC domain in an MLL-AF9 fusion protein to confer an enhanced 
proliferative capacity on murine bone marrow progenitor cells, in vitro bone marrow 
colony assays were performed.  As described previously for the CXXC point mutation 
constructs, the MLL-AF9 CXXC domain swap retroviruses were introduced by 
spinoculation into c-Kit+ murine bone marrow progenitor cells then plated in 
methylcellulose with appropriate cytokines.  After one week, colonies and cells were 
counted, then cells were replated for up to four weeks.  We hypothesized that only those 
MLL-AF9 constructs containing CpG-binding domains that could bind to unmethylated 
CpG DNA in vitro would be able to function in MLL-AF9 in a colony assay to promote 
cell proliferation.  As expected, the MLL(MLL CXXC)-AF9 construct was highly 
transforming (see point mutation data) and the MSCVneo infected cells died in the first 
couple of weeks (Figure 15A).  MLL(DNMT1 CXXC)-AF9 showed robust in vitro 
colony forming activity, with no statistically significant difference to MLL-AF9.  
However, MLL(CGBP CXXC)-AF9, MLL(MBD1 CXXC)-AF9, and MLL(MBD1 
MBD)-AF9 were not transforming and showed very poor colony forming ability.  The 
average numbers of colonies at week 4 for these constructs showed no statistically 
significant difference to MSCVneo but did show a statistically significant decrease as 
compared to MLL-AF9.  Those few colonies that persisted for these constructs were  
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Figure 15.  MLL-AF9 CXXC Domain Swap Bone Marrow Colony Assay 
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(A) Average colony numbers for weeks 2-4 after plating primary mouse bone c-Kit+ 
progenitor cells expressing MLL-AF9 or MLL-AF9 with indicated CXXC domain swaps 
in methylcellulose, with error bars representing standard error from 6-8 independent 
biological replicates.  (B) Digital photographs showing colony and cell morphologies at 
week 4 of the colony assay.  
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often diffuse in nature and typical of differentiated bone marrow cells, with few cell 
numbers (Figure 15B).  The MLL-AF9 and MLL(DNMT1 CXXC)-AF9 cells formed  
dense compact round colonies typical of bone marrow progenitor cells.  Cell counts over 
the course of the replating experiment revealed that MLL-AF9 and MLL(DNMT1 
CXXC)-AF9 both conferred an approximately 870-fold expansion of cell number at each 
replating, whereas for the remaining constructs the cell expansion ranged from 3 to 7-
fold.  Cytospins of the bone marrow cells taken from week 3 or 4 of the colony assays 
also confirm that the transformed MLL-AF9 and MLL(DNMT1 CXXC)-AF9 cells 
primarily resemble leukemic blasts, while the other constructs produce a more 
heterogeneous differentiated bone marrow cell population (Figure 15B).  
 Because the domains from MBD1 are not able to function in MLL-AF9, our 
hypothesis that MLL CXXC must maintain the ability to bind to unmethylated DNA in 
order to transform bone marrow cells was supported.  However, we expected that both 
CGBP and DNMT1 CXXC domains would replace the MLL CXXC domain in the 
context of the MLL-AF9 fusion because the isolated domains bind to the nonmethylated 
CpG-containing DNA in vitro.  The ability of a CXXC domain to replace the MLL 
CXXC domain did not strictly correspond with DNA binding affinity, however, because 
the CXXC domain from CGBP has a higher affinity for DNA binding as compared to the 
DNMT1 CXXC domain (Figure 13).  These results suggest that CXXC DNA binding 
affinity alone is not the only function of this domain necessary for MLL-AF9 
transformation. 
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DNMT1 CXXC domain can functionally replace the MLL CXXC domain in an 
MLL fusion protein in an in vivo leukemia assay 
 
 In order to determine if the alternate CpG binding domains can function in the 
place of the MLL CXXC domain in an MLL-AF9 fusion protein to promote 
leukmogenesis, in vivo leukemia assays were performed in mice.  MSCVneo, MSCV-
MLL(MLL CXXC)-AF9-Flag, MSCV-MLL(CGBP CXXC)-AF9-Flag, MSCV-
MLL(DNMT1 CXXC)-AF9-Flag, MSCV-MLL(MBD1 CXXC)-AF9-Flag, and MSCV-
MLL(MBD1 MBD)-AF9-Flag retroviruses were used to infect CD45.1+ c-Kit+ murine 
bone marrow progenitor cells.  As described for the CXXC point mutations, the infected 
cells were transplanted into lethally irradiated recipient mice, and then the mice were 
monitored for leukemia development.   
 As seen in Figure 16A, all of the MLL-AF9 mice (n = 7) and six of the seven 
MLL(DNMT1 CXXC)-AF9 mice developed acute myeloid leukemia with mean latencies  
of 89 and 73 days, respectively.  Median whole blood counts assayed with the Hemavet 
at time of sacrifice were 16.2 K cells per μL for the MLL-AF9 mice and 17 K per μL for 
the MLL(DNMT1 CXXC)-AF9 mice.  None of the MLL(CGBP CXXC)-AF9 (n=7), 
MLL(MBD1 CXXC)-AF9 (n=8), and MLL(MBD1 MBD)-AF9 (n=6), or MSCVneo 
mice (n=4) developed leukemia during the course of the experiment which extended 260 
days.  The median whole blood count of all the healthy mice at time of sacrifice was 8.8 
K per μL.  Average whole blood counts for all mice are summarized in Table 8.  A small 
number of the mice that did not develop leukemia (one mouse each receiving 
MLL(DNMT1 CXXC)-AF9, MLL(MBD1 CXXC)-AF9, or MSCVneo and two mice 
receiving the MLL(MBD1 MBD)-AF9), died from other causes (thymus or liver tumors) 
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Table 8.  MLL leukemia development in mice reconstituted with MLL-AF9 or 
MLL(DNMT CXXC)-AF9  
 
Construct 
Average 
Latency 
(days ± s.d.) 
Average CBC  
(K per μL ± s.d.) 
Range of 
CBCs  
(K per μL) 
Average 
Spleen Weight 
(grams ± s.d.) 
MLL-AF9 
n = 7 89 ± 32 43 ± 50 8 - 140 0.39 ± 0.19 
MLL(DNMT 
CXXC)-AF9 
n = 7 
73 ± 36 20 ± 6 14 - 29 0.29 ± 0.13 
MLL(CGBP 
CXXC)-AF9 
n = 7 
- 7.5 ± 4 2.6 - 14 0.07 ± 0.01 
MLL(MBD1 
CXXC)-AF9 
n = 8 
- 7.6 ± 4 3.6 - 15 0.08 ± 0.01 
MLL(MBD1 
MBD)-AF9 
n = 6 
- 9.3 ± 6 3 – 16 0.06 ± 0.01 
MSCVneo 
n = 4 - 
11.4 ± 2.4 9 - 13 0.08 ± 0.01 
 
during the course of the experiment.  However, these tumor cells did not express the 
CD45.1 marker from the donor cells.  Therefore, the tumors were unrelated to MLL-AF9 
expression and were likely a side effect of the radiation dose that the recipients received 
prior to transplant.  The complete blood counts and spleen weights of the mice that died 
of other causes were not included in the analysis seen in Table 8.  The mice that 
developed leukemia had an increased number of blast cells in their peripheral blood and 
bone marrow as seen in Figure 16B.  Spleens of the leukemic mice were enlarged and 
had an average weight five times that of the healthy mice (Table 8).  Organs sections of 
the spleen, liver, lungs and kidneys from the MLL-AF9 and MLL(DNMT1 CXXC)-AF9  
mice displayed infiltration of leukemic cells, while the other mice had normal organ 
histology (Figure 16C).   
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Figure 16. In vivo MLL-AF9 CXXC Domain Swap Leukemia Assay 
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(A) Survival curve of mice transplanted with bone marrow progenitor cells expressing 
MLL-AF9 or MLL-AF9 CXXC domain swap fusion proteins.  (B) Peripheral blood 
smears and bone marrow samples taken from indicated mice at time of sacrifice.   
(C)  Digital photographs of spleen, liver, lungs, and kidney sections stained with 
Hematoxylin and Eosin and taken from MLL-AF9 or MLL(DNMT CXXC)-AF9 mice at 
time of sacrifice due to leukemia or healthy MSCVneo, MLL(CGBP CXXC)-AF9, 
MLL(MBD1 CXXC)-AF9, or MLL(MBD1 MBD)-AF9 nine months after bone marrow 
transplants. 
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Peripheral blood and bone marrow cells taken from the mice at time of sacrifice were 
subjected to flow cytometry using a variety of antibodies directed at mouse hematopoietic  
cell surface markers.  Anti-CD45.1 antibody was included with most of the groups to use 
for gating of the donor MLL-AF9 or CXXC domain swap expressing cells.  The first 
group of antibodies was directed at markers of bone marrow myeloid cells and progenitor 
cells and included anti-CD45.1, CD11b, Gr-1, CD117, and Sca-1.  These marks would be 
expected to be present with MLL-AF9 myeloid leukemia.  The second group of 
antibodies added in marks for B cells and included anti-CD45.1, CD11b, B220, Gr-1, 
CD117 and CD19.  The third group incorporated markers for T cells and included anti-
CD45.1 (for bone marrow cell analysis only), CD8a, CD4, CD25, CD3e, CD44 and 
CD117 (for peripheral blood cell analysis only). The fourth group of antibodies included 
markers for erythroid, megakaryoctye and NK cells and included anti-CD45.1, CD41, 
TER119, CD117, and CD49b/DX5.  These other antibodies were included to test if any 
mixed lineage leukemias or other hematopoietic proliferative disorders had developed in 
any of the mice.  As seen in Figure 17, the bone marrow of the leukemic mice most often 
showed a very high percentage of cells expressing CD45.1, indicating that the 
transplanted cells expressing MLL-AF9 or MLL(DNMT1 CXXC)-AF9 had a 
proliferative advantage over any other bone marrow cells present and had repopulated the 
bone marrow.  The healthy mice all showed a very low percentage of CD45.1+ cells in 
their bone marrow (Figure 17).  The CD45.1+ bone marrow and peripheral cells in the  
leukemic mice were gated upon for analysis.  Nearly 100% of these CD45.1+ cells 
expressed myeloid markers CD11b and Gr-1, while a lower percentage of cells expressed 
progenitor markers c-Kit/CD117 and Sca-1, as would be expected for acute myeloid 
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Figure 17.  FACS profiles of bone marrow cells from leukemic or healthy mice with 
MLL-AF9 or CXXC domain swapped MLL-AF9  
 
 
 
 
 
 
 
CD45.1 indicates transplanted cell population expressing the MLL-AF9 or CXXC 
domain swap construct.  The second and third panels show the percentage of CD45.1 
positive cells from the MLL-AF9 and MLL(DNMT CXXC)-AF9 mice or total bone 
marrow cells from the healthy MLL(MBD1 CXXC)-AF9 mouse that express myeloid 
markers CD11b and Gr-1, and progenitor markers CD117 and Sca-1.   
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leukemia (Figure 17).  The CD45.1+ bone marrow and blood cells were negative for B 
cell markers B220 and CD19, T cell markers CD3e, CD8a, CD4 and CD25,  
magakaryocyte marker CD41, erythroid marker TER119, and NK cell marker CD49b.  
All bone marrow cells expressed CD44 as expected.  Whole bone marrow cells taken  
from a healthy MLL(MBD1 CXXC)-AF9 mouse showed a more mixed population of 
cells as compared to the leukemic mice with lower percentages of cells expressing 
CD11b, Gr-1, CD117 and Sca-1 (Figure 17), along with populations of cells expressing 
the B cell, T cell and other markers (data not shown).  The results of the leukemia assay 
corroborated the colony assay results in that of the CpG-binding domains tested, DNMT1 
CXXC alone can functionally replace the MLL CXXC domain in an MLL-AF9 fusion 
protein.  While DNA binding activity of the CXXC domain appears to be essential for 
MLL-AF9 to function in causing leukemia, it is not sufficient, as the CGBP CXXC 
domain, which is able to bind unmethylated DNA, is not able to function in the context of 
MLL-AF9.    
DNMT1 CXXC domain can functionally replace the MLL CXXC  
domain in an MLL fusion protein to promote overexpression  
of Hoxa9 in bone marrow progenitor cells 
 
 MLL fusion proteins frequently cause upregulation of HOXA9 in MLL leukemias, 
and this HOXA9 overexpression has been linked to disease progression.7, 72  Due to the 
importance of HOXA9 upregulation to MLL leukemia, we hypothesized that only those 
MLL-AF9 CXXC domain swap proteins which transform bone marrow cells would be 
able to cause overexpression of Hoxa9.  In order to determine if the MLL-AF9 CXXC 
domain swap proteins cause upregulation of Hoxa9 expression, RNA was isolated from 
bone marrow progenitor cells expressing the domain swap fusion proteins after one week 
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of culture in methylcellulose.  Quantitative real-time RT-PCR was performed using 
Taqman probes to determine Hoxa9 expression levels.  MLL-AF9 and MLL(DNMT 
CXXC)-AF9 proteins promote high levels of expression of Hoxa9, while the other 
domain swap fusion proteins that were non-transforming do not cause overexpression of 
Hoxa9, similar to MSCVneo vector infected cells (Figure 18A).  The low levels of Hoxa9 
expression help explain why the MLL-AF9 fusion proteins with the CGBP CXXC, 
MBD1 CXXC or MBD1 MBD domain were unable to transform bone marrow progenitor 
cells. 
MLL fusion proteins can localize to the Hoxa9 locus regardless of which  
CpG binding domain replaces the MLL CXXC domain 
 
 I had previously shown that while MLL CXXC DNA binding is essential to 
protect target CpGs in Hoxa9 from becoming methylated and to cause overexpression of 
Hoxa9 transcription, DNA binding activity of the CXXC domain is not essential for 
MLL-AF9 proteins to localize to the Hoxa9 locus.10  Therefore, we hypothesized that all 
of the CXXC domain-swapped MLL-AF9 proteins would be able to localize to Hoxa9.  
In order to determine if MLL-AF9 domain swap constructs which do not cause 
overexpression of Hoxa9 still bind to the locus, chromatin immunoprecipitation (ChIP) 
assays were performed with mouse bone marrow progenitor cells expressing the MLL-
AF9 domain swap constructs.  Anti-Flag antibody or IgG control was used to 
immunoprecipitate chromatin.  DNA was isolated then analyzed by real time PCR using 
primers that localize to the alternate upstream AB exon of Hoxa9, a region which we 
have previously shown MLL binding.6  As seen in Figure 18B, all of the MLL-AF9 
CXXC domain swap proteins bind to the Hoxa9 locus, regardless of their ability to  
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Figure 18. Hoxa9 expression and fusion protein binding to the Hoxa9 locus in bone 
marrow cells expressing MLL-AF9 or MLL-AF9 with substituted CXXC domains   
 
 
 
 
(A) Quantitative RT-PCR for Hoxa9 in bone marrow cells expressing the indicated 
constructs. Shown are mean relative expression levels from two independent experiments 
each done in triplicate, with error bars indicating standard deviation.  (B) Chromatin 
immunoprecipitation assay from c-Kit+ mouse bone marrow cells expressing the 
indicated constructs.  Anti-Flag or IgG was used to IP chromatin and real-time PCR was 
performed in triplicate with primers that amplify an MLL-binding region in the Hoxa9 
locus.  Results were normalized to input chromatin.  Fold increase in binding with anti-
Flag antibody over IgG to the Hoxa9 locus is shown.  Experiments were repeated three 
times, with error bars indicating standard deviation. 
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activate transcription of the locus.  As expected, the MSCVneo vector control does not 
show enrichment of anti-Flag over IgG binding to this region of Hoxa9 (data not shown).  
Surprisingly, the MLL(MBD1 CXXC)-AF9 and MLL(MBD1 MBD)-AF9 proteins seem 
to have an increased presence on Hoxa9 compared to MLL-AF9 and the other domain 
swap proteins.  These results support the hypothesis that the specific DNA binding 
activity of the MLL CXXC domain is not absolutely required for MLL-AF9 protein 
localization to gene targets. 
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CHAPTER 5 
DISCUSSION 
 Many transcription factors contain protein domains that bind to specific DNA 
sequence motifs.122  This allows transcriptional activation to be highly regulated in cells.  
When a certain transcription factor is expressed, it will in turn initiate the transcription of 
a specific set of target genes to which the transcription factor can bind.  For example, the 
general transcription factor TBP, or TATA-binding protein, binds specifically to TATA 
box-containing gene promoters.122  HOX proteins bind to specific target genes through 
their DNA-binding homeodomains which recognize the DNA motif TAAT in gene 
promoters.69  In Drosophila, Polycomb Group and Trithorax proteins are recruited to 
regulatory sequences called Polycomb response elements, PREs, and Trithorax response 
elements, TREs, respectively.123  MLL and MLL fusion proteins, however, have long 
stumped researchers as to how they recognize and bind to target genes, and a specific 
DNA binding consensus sequence has not been identified.  The DNA binding function of 
the MLL CXXC domain was initially hypothesized to contribute, along with the MLL 
AT hooks, to MLL’s localization to specific target genes.  We now know from structural 
studies that MLL CXXC domain binding centers specifically on one nonmethylated CpG 
dinucleotide, while flanking DNA sequences contribute to CXXC domain-DNA binding 
via non-specific interactions only.9, 10  This suggests that the MLL CXXC domain could 
interact with any nonmethylated CpG-containing DNA, rather than a specific consensus
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sequence that may appear in the promoters of MLL target genes.  In this study, we set out 
to examine the functional roles of the MLL CXXC domain as it contributes to MLL 
fusion protein leukemogenesis.  Through CXXC point mutation and domain swap 
studies, we hoped to learn how the MLL CXXC domain contributes to MLL-AF9 target 
localization and promotion of target gene overexpression which leads to leukemia 
development.  We hypothesized that the DNA binding function of the MLL CXXC 
domain would be essential for MLL fusion proteins to bind to target genes, protect target 
CpG DNA from methylation, cause overexpression of target genes, give bone marrow 
progenitor cells an enhanced proliferative capacity in vitro, and to cause leukemia in vivo.  
In the domain swap experiments, we hypothesized that only those DNA binding domains 
with known properties most similar to the MLL CXXC domain would be able to function 
in an MLL-AF9 fusion protein.    
 Previous studies have shown that the presence of the MLL CXXC domain is 
essential for MLL fusion proteins to promote transformation of bone marrow progenitor 
cells in vitro.8  However, these previous studies did not address maintaining the structural 
integrity of this domain.  In the first aim of this study, I wished to determine if the DNA 
binding function of the MLL CXXC domain is essential for MLL fusion proteins to 
function.  John Bushweller’s laboratory at the University of Virginia solved the structure 
of the MLL CXXC domain in complex with DNA.  This allowed them to identify the 
CXXC domain amino acids which specifically contribute to binding to the unmethylated 
CpG DNA, and to generate point mutations that would disrupt these interactions.  
Importantly, The Bushweller laboratory used NMR to check that each amino acid 
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substitution would still allow proper zinc-coordination and folding of the CXXC domain.  
Therefore, I would be able to conclude that any functional effects seen would be due 
specifically to loss of DNA binding rather than disruption of the structure of the CXXC 
domain.   
 I introduced several CXXC point mutations into an MSCVneo-MLL-AF9-Flag 
retroviral construct and performed colony formation assays with murine bone marrow 
progenitor cells in order to determine if the DNA binding function of the MLL CXXC 
domain is critical to MLL fusion proteins to promote oncogenic transformation.  The 
point mutations at DNA interacting amino acids included R1154A, K1185A and 
Q1187A, which reduced the isolated MLL CXXC DNA binding affinity by 6-15 fold 
compared to a wild type MLL CXXC domain.  The C1188D point mutation, at one of the 
non-conserved and non-zinc-coordinating cysteines, abolished all detectable binding of 
the isolated CXXC domain to DNA.  While cysteine1188 does not contact target DNA 
directly, it is in very close proximity to the CpG and it is expected that mutation to 
aspartic acid introduces a repulsive interaction with the DNA that is strong enough to 
ablate CXXC DNA binding ability.  Mutation of cysteine1188 to alanine (C1188A), 
however, was inert in that it did not alter the isolated MLL CXXC DNA binding affinity 
as compared to the wild type domain.  The results of the colony assays correlated highly 
with the in vitro DNA binding affinities of the point mutant MLL CXXC domains.  The 
MLL(C1188A)-AF9 mutant behaved similar to an unmutated MLL-AF9, producing 
many bone marrow colonies.  The R1154A, K1185A and Q1187A point mutations gave 
MLL-AF9 a much reduced colony forming ability, while the C1188D point mutant in 
MLL-AF9 gave a phenotype similar to MSCVneo, often with no colonies surviving into 
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the third or fourth week of the assay.  From these experiments, I concluded that the DNA 
binding ability of the MLL CXXC domain is essential for MLL fusion proteins to 
promote the transformation of bone marrow progenitor cells in vitro.   
 In order to determine if the MLL CXXC DNA binding function was also essential 
for MLL fusion proteins to promote leukemogenesis in vivo, the MLL(C1188A)-AF9 and 
MLL(C1188D)-AF9 retroviral constructs were used to infect murine bone marrow 
progenitor cells which were then transplanted into irradiated recipient mice.  These mice 
were then monitored for leukemia development.  Confirming the in vitro DNA binding 
and colony assay results, all of the mice with the normal DNA binding C1188A point 
mutation developed MLL leukemia.  These mice had a shorter latency to leukemia 
development than mice expressing unmutated MLL-AF9.  The mice expressing the DNA 
binding deficient MLL(C1188D)-AF9 construct or MSCVneo did not develop leukemia 
throughout the course of the experiment.  These results confirm that the DNA binding 
function of the MLL CXXC domain is an essential function that contributes to MLL 
fusion proteins ability to promote leukemia. 
 These experiments were followed by in vitro assays designed to understand the 
mechanism of action of the MLL CXXC domain.  The MLL-AF9 CXXC point mutations 
C1188A and C1188D were again used to determine how these mutant proteins affect and 
act upon the MLL target gene Hoxa9, which has previously been shown to be an 
important gene that gets upregulated in MLL leukemias.7, 72  Our laboratory has also 
shown that MLL binds to the Hoxa9 locus, and protects specific target CpGs in this 
region from becoming DNA methylated.6  MLL(C1188A)-AF9 and MLL(C1188D)-AF9 
constructs were expressed in Mll-/- MEFs to assay their ability to protect target CpG 
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DNA from DNA methylation.  As expected, the CpGs that previously showed MLL and 
MLL-AF4 dependent DNA methylation protection showed higher levels of DNA 
methylation in cells transfected with MLL(C1188D)-AF9 or the MSCVneo vector, as 
compared to cells expressing MLL(C1188A)-AF9.  From this experiment, we concluded 
that the MLL and MLL fusion protein function of DNA methylation protection on target 
CpG DNA is facilitated by the DNA binding activity of the MLL CXXC domain.  DNA 
methylation protection results also correlated with Hoxa9 expression.  Real time RT-PCR 
on bone marrow colony assay cells showed that MLL(C1188A)-AF9 was able to promote 
overexpression of Hoxa9 and miR196b, while the MLL fusion with the binding deficient 
CXXC point mutation, MLL(C1188D)-AF9, was unable to cause overexpression of 
Hoxa9 over the level of cells infected with MSCVneo vector alone.  This suggests that 
the DNA binding function of the MLL CXXC domain, perhaps through its DNA 
methylation protection function, is necessary for MLL fusion proteins to promote 
overexpression of target genes.   
 Following these experiments, the question remained as to whether the DNA 
binding function of the CXXC domain of MLL is necessary for an MLL fusion protein to 
localize to its target genes.  As the CXXC domain is one of two known DNA binding 
domains in the MLL protein, one might hypothesize that its binding function must remain 
intact in order for MLL to locate and bind appropriately to its target genes.  However, 
MLL and MLL fusion proteins interact with many other DNA binding proteins, and the 
CXXC domain does not bind to a specific DNA sequence outside of one unmethylated 
CpG, a motif which appears in the promoters of many genes.  In order to address this 
question, Phoenix cells were transfected with MLL(C1188A)-AF9 and MLL(C1188D)-
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AF9 constructs and chromatin immunoprecipitation assays were performed.  Antibodies 
including anti-Flag for the fusion proteins, anti-RNA Polymerase II as a mark of active 
transcription, and anti-trimethylated H3K9 as a mark of repression were used to 
immunoprecipitate DNA-protein chromatin complexes, then real time PCR was 
performed using primers to the upstream region of Hoxa9 that shows MLL-dependent 
DNA methylation protection.  Interestingly, we saw no significant differences in the 
binding of MLL(C1188A)-AF9 and MLL(C1188D)-AF9 to Hoxa9.  Similarly, RNA 
Polymerase II showed just a small insignificant decrease in binding to Hoxa9 in cells 
expressing MLL(C1188D)-AF9 as compared to MLL(C1188A)-AF9.  The biggest 
difference observed was in the increased presence of the trimethylated H3K9 mark, 
which is a mark of transcriptional repression, on Hoxa9 chromatin in cells expressing 
MLL(C1188D)-AF9 compared to cells expressing MLL(C1188A)-AF9.   
 From these experiments, we concluded that the DNA binding function of the 
MLL CXXC domain is not critical for MLL fusion proteins to localize to Hoxa9.  This 
therefore suggests that the DNA binding MLL CXXC domain is not involved in the 
targeting of MLL or MLL fusion proteins to MLL target genes.  Instead, we expect DNA 
interactions via the MLL AT hooks,23 possibly in combination with interactions with 
proteins such as Menin and LEDGF,26, 27, 48 which also bind to DNA and chromatin, to be 
important for MLL target localization.  The MLL CXXC domain, however, does have a 
necessary function once an MLL fusion protein locates its target gene.  The MLL CXXC 
domain binds to specific unmethylated CpGs in the gene locus and acts to keep these 
CpGs in the unmethylated state.  This in turn helps promote an active state of 
transcription in the gene locus.  When the DNA binding activity of the MLL CXXC 
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domain is disrupted, as in the case of the MLL(C1188D)-AF9 protein, while the fusion 
protein still localizes to Hoxa9, the CXXC domain cannot protect the target CpGs from 
becoming methylated.  This DNA methylation then promotes a state of repression for 
Hoxa9, which includes the recruitment of histone H3K9 trimethylation which helps keep 
the gene silenced (Figure 19).   
 Overall, to summarize the results from my first aim, MLL-AF9 requires CXXC 
DNA binding in order to give bone marrow cells an enhanced proliferative capacity in 
vitro, to cause leukemia in vivo, to promote overexpression of target gene Hoxa9 and to 
protect target Hoxa9 CpGs from becoming DNA methylated, but not to localize to 
Hoxa9.  We can conclude that the DNA binding function of the MLL CXXC domain is a 
critical function for MLL fusion proteins.  This conclusion suggests that the MLL CXXC 
domain could be a potential therapeutic target for MLL leukemia.  If a specific inhibitor 
could be developed that could interact with the DNA binding amino acids within the 
CXXC domain such that they would no longer be available for DNA binding, then the 
MLL fusion proteins could not promote leukemogenesis.  Our collaborators in the 
Bushweller laboratory are currently searching for an appropriate small molecule 
inhibitor.  This inhibitor could be tested first in vitro in CXXC binding assays then in 
MLL-AF9 bone marrow colony assays to determine efficacy, then in vivo in mice to 
determine any potential side effects.   
 One potential negative aspect of this approach is that a CXXC inhibitor may also 
target the CXXC domain of the wild type MLL protein in patients.  As MLL is an 
essential gene for proper blood cell development, this could be detrimental to the normal 
hematopoiesis process in the patient and affect blood cell counts.  However, most current  
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Figure 19.  Model of the regulation of Hoxa9 locus transcription by the CXXC 
domain of MLL-AF9 
 
 
 
B 
A 
 
(A) The CXXC domain of MLL-AF9 protects specific CpG sequences within the Hoxa9 
locus from methylation and maintains transcription within the locus; (B) disruption of 
DNA binding function of CXXC domain by C1188D mutation results in increased 
methylation of the same CpGs, increased H3K9 methylation, and silencing of Hoxa9 and 
mir196b.  Models were developed in collaboration with John Bushweller, University of 
Virginia. 
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chemotherapy treatments also negatively affect blood cell populations, so the proper 
dosage may be able to distinguish effects on wild type versus MLL fusion proteins.  In 
addition to targeting the MLL CXXC domain, a potential small molecule inhibitor would 
need to be tested for binding to other proteins that contain CXXC domains.  If the drug 
also binds to any of these proteins, such as DNMT1 or CGBP, additional effects would 
need to be analyzed, such as changes to global genomic DNA methylation and histone 
methylation patterns, and the possibility of future diseases, such as cancer, arising from 
these changes.   
 During the course of the MLL-AF9 CXXC point mutation in vivo leukemia 
assays, it was noted that all of the MLL(C1188A)-AF9 mice developed leukemia rather 
quickly as compared to the unmutated MLL-AF9 mice.  The average latencies were 39.5 
days for the MLL(C1188A)-AF9 mice and 94 days for the MLL-AF9 mice.  The final 
average white blood cell counts and spleen weights at time of sacrifice were also slightly 
increased in the MLL(C1188A)-AF9 mice as compared to the MLL-AF9 mice.  This 
more severe phenotype suggests that the MLL(C1188A)-AF9 construct has a more potent 
oncogenic activity compared to the unmutated MLL-AF9.  While it is possible that these 
effects could be due to differences in viral titers used to infect the donor bone marrow 
cells, we would not expect this to cause such a big difference in latency.  MLL fusion 
proteins are directly responsible for promoting transformation of bone marrow cells, but 
it is also thought that a number of other genetic mutations must occur in a cell before a 
mouse or a human develops leukemia.  Therefore, it was unexpected to see all of the 
MLL(C1188A)-AF9 mice develop leukemia so quickly, and we hypothesized that the 
C1188A mutation may have an effect on MLL-AF9 function.   
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 The amino acid cysteine contains a thiol group in its side chain, and can often 
create a disulfide bond with a nearby partner cysteine.124  Cysteine1188 in MLL is not 
thought to have a cysteine partner, as it is not involved with the other CXXC cysteines in 
coordinating the zinc ions, and because it is in close proximity to the CpG when the 
domain is bound to DNA, it is not likely to form bonds with cysteines from other protein 
domains.  We hypothesize that cysteine1188 may be acting as a redox sensor for the 
MLL CXXC domain.  Under certain cellular conditions, cysteine1188 may be oxidized.  
The addition of such a post-translational modification would make cysteine1188 more 
bulky and would likely inhibit CXXC DNA binding affinity, similar to when 
cysteine1188 was mutated to aspartic acid.  Alternatively, when cysteine1188 is in the 
reduced state, with its normal unmodified thiol group, it allows the CXXC domain to 
bind to DNA.  We suspect that the introduction of an alanine, which cannot be oxidized, 
in place of cysteine1188 allows DNA binding to occur at all times; the redox switch 
thereby becomes bypassed and DNA binding can occur under all oxidative cellular states.  
Therefore we hypothesize that the MLL(C1188A)-AF9 mice develop leukemia faster 
because the CXXC domain is able to bind to target DNA at all times, rather than being 
subject to regulation as a redox sensor or by some other post-translational modification.    
 MLL CXXC domain swap experiments were performed to gain further 
understanding of the role of the CXXC domain and how it contributes to MLL 
leukemogenesis.  These experiments allowed us to understand if the MLL CXXC domain 
is unique in its ability to help MLL fusion proteins promote leukemia, or if similar CXXC 
domains from other proteins share enough similarities with the MLL CXXC domain that 
they can also function in MLL-AF9.  Several CpG-DNA binding domains, which have 
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known properties both similar to and different from the MLL CXXC domain, were 
chosen to swap into MLL-AF9.  The first domain chosen was the CXXC domain from 
the CpG binding protein, CGBP, also known as CFP1.  This domain was expected to 
have the most similarity to the MLL CXXC domain because it is also known to bind only 
to nonmethylated CpG DNA, and is also present in a protein that promotes active 
transcriptional chromatin states.121  The second domain chosen for the domain swap 
project was the CXXC domain of the maintenance DNA methyltransferase protein 
DNMT1.  It was initially thought that the DNMT1 CXXC domain could bind to 
hemimethylated DNA, which is the preferential substrate of DNMT1 enzymatic 
activity.109  Recent structural data, however, shows that the DNMT1 CXXC domain, like 
most CXXC domains, binds to unmethylated CpG DNA.96  Finally two domains were 
chosen from the repressor methyl binding domain protein MBD1.  The MBD1 transcripts 
can undergo splicing which results in the proteins having either two or three CXXC 
domains.93  These CXXC domains from the mouse Mbd1 protein were tested in vitro for 
DNA binding activity, and only the third CXXC domain, which shows the most sequence 
identity to the MLL CXXC domain, showed an ability to bind to unmethylated DNA.  
The first two CXXC domains of Mbd1 were unable to bind to CpG-containing DNA 
targets, regardless their DNA methylation status.111  We chose to study the first CXXC 
domain from MBD1, which has the least amino acid sequence identity to the MLL 
CXXC domain and high identity to its murine Mbd1 homolog, for swapping into MLL-
AF9.  Finally, we also chose to swap in the methyl binding domain, or MBD domain, 
from MBD1.  This domain is different from CXXC domains structurally and is only able 
to bind to methylated CpG DNA.92  We hypothesized that because the CGBP CXXC 
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domain seems to have the most similarities to the MLL CXXC domain, it would be able 
to function in MLL-AF9, while the other domains would behave differently and 
negatively affect MLL-AF9 function. 
 While the binding specificities of the different CXXC and MBD domains used in 
this study were previously characterized, their binding affinities relative to each other 
were never directly compared.  In order to determine the differences in DNA binding 
affinities of the CpG DNA binding domains, the isolated proteins were purified from 
bacterial lysates and fluorescence polarization was used to determine their binding to 
unmethylated CpG DNA.  The sequence of the DNA probe was derived from a region of 
Hoxa9 that our lab previously showed to interact with the MLL CXXC domain.6  The 
results showed that the MLL CXXC domain bound with the strongest affinity to the 
unmethylated DNA, followed by the CGBP CXXC domain with 7 fold lower affinity, 
then the DNMT1 CXXC domain at 34 fold lower binding affinity than the MLL CXXC 
domain.  The MBD1 MBD and CXXC domains were unable to bind to the unmethylated 
DNA as expected.   
 The MBD1 CXXC domain lacks a KFGG motif that is conserved in many CXXC 
domains (Figure 20A).  This motif has also been shown to be essential to MLL fusion 
protein function in colony assays, as mutation of this motif to AAAA causes lack of bone 
marrow colony formation.8  In addition, the KFGG to AAAA mutation causes the MLL 
CXXC domain to be unable to coordinate zinc ions.9  This suggests that the KFGG motif 
is necessary for proper folding of the MLL CXXC domain, and perhaps other CXXC 
domains.  The KFGG amino acids appear at the sharp turn at the top of the domain and 
the two glycines are thought to be necessary to facilitate the folding of this structure due 
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to their small molecular size.  In addition to the folding considerations, the lysine in the 
KFGG motif, which appears at amino acid 1178 in MLL, makes contact with the DNA 
phosphate backbone and therefore also contributes to CXXC DNA binding.  Lysine1178 
is a proline in the MBD1 CXXC domain which would be unlikely to functionally 
substitute for a lysine for DNA binding.  
 It was interesting that the MLL, CGBP and DNMT1 CXXC domains showed 
such a large range of DNA binding affinities to the unmethylated DNA, which is the 
preferred DNA binding target of all of the proteins.  We learned from our structural 
studies which of the MLL CXXC amino acids contribute to DNA binding.10  The 
differences in binding affinities between the CXXC domains could be due to differences 
in these amino acids (Figure 20A).  The main recognition motif for the unmethylated 
CpG in the MLL CXXC domain is the amino acid loop 1182-1188; these amino acids 
either directly bind to or structurally accommodate the CpG DNA motif.10  Of those 
amino acids that directly contribute to binding, lysine1185 and isoleucine1184 appear 
only in MLL, while glutamine1187 is present in MLL, CGBP and DNMT1, and 
lysine1186 appears in MLL and DNMT1 but not CGBP.  Of the other amino acids in the 
1182-1188 loop, arginine1182 and cysteine1188 are present only in MLL, and 
asparagine1183 is in MLL and CGBP.  Of the other amino acids in the MLL CXXC 
domain that contribute non-specific binding interactions with the backbone or the minor 
groove of the DNA, several are not conserved in DNMT1 or CGBP: serine1152, 
lysine1176, lysine1190, lysine1193 and leucine1197.  Arginine1150 is conserved 
between MLL and CGBP, arginine1154 is conserved between MLL and DNMT1, and 
just two amino acids are conserved between all three proteins: lysine1178 and  
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Figure 20.  CXXC amino acids highlighted by conservation to explain functional 
specificity of the domain in the context of an MLL-AF9 fusion   
 
 
 
(A) CXXC domains are aligned to show sequence conservation. Identical residues to 
MLL are shaded in grey, while boxed residues highlight differences.  Red residues are 
identical in MLL and DNMT1 but not present in CGBP of MBD1 CXXC.  Green 
residues are conserved in CGBP and MBD1 but not present in MLL CXXC.  The blue 
Cysteine 1188 is conserved in vertebrate MLL paralogs but is alanine in DNMT1.  (B) 
Solution structure of MLL CXXC domain in complex with palindromic CpG DNA (PDB 
ID: 2KKF). MLL CXXC domain is shown as a space filling model in contact with the 
ball and stick structure of DNA, in four orientations.  The same color scheme is used as 
in (A).  Protein models were provided by Noah Birch. 
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arginine1192.10  So, while the spacing of the zinc-coordinating cysteines and a few other 
amino acids are highly conserved between CXXC domains, many of the amino acids that 
are involved in binding to DNA in the MLL CXXC are not present in the other CXXC 
domains.  The variation in amino acid sequences between CXXC domains likely 
contributes to the different DNA binding affinities measured.       
 The CXXC and MBD domains were introduced into MLL-AF9 fusion proteins in 
the place of the MLL CXXC domain and tested in vitro in bone marrow colony assays 
and in vivo in murine leukemia assays.  I previously showed that DNA binding activity is 
essential to MLL CXXC domain function.  Therefore, it was expected that the CGBP  
CXXC domain, which has the closest DNA binding affinity to MLL CXXC, would be 
able to function in MLL-AF9 bone marrow colony assays and leukemia assays, but the 
other domains would confer a reduced function to MLL-AF9 and therefore show reduced 
colony formation and ability to cause MLL leukemia in mice.  As expected, the 
MLL(MBD1 CXXC)-AF9 and MLL(MBD1 MBD)-AF9 constructs were not able to 
promote bone marrow colony formation or in vivo leukemia development.  This 
confirmed my previous observations that the CXXC domain in MLL must be able to bind 
to unmethylated CpG DNA for MLL fusion proteins to transform bone marrow cells in 
vitro and cause leukemia in vivo.  Surprisingly, MLL(DNMT1 CXXC)-AF9 was able to 
promote colony formation and leukemia while MLL(CGBP CXXC)-AF9 was not.  
Because CGBP CXXC domain has a higher DNA binding affinity than DNMT1 CXXC 
domain, we can conclude that CpG-DNA binding ability, while essential, is not sufficient 
for a CXXC domain to contribute to MLL-AF9 function.  This suggests that the DNMT1 
CXXC domain must share an important function with the MLL CXXC domain that is not 
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present in the CGBP CXXC domain.  I expected that this shared function between the 
MLL and DNMT1 CXXC domains is the ability to recruit some cofactor that is essential 
for the activation of MLL target gene expression.     
 Hoxa9 expression in MLL-AF9 CXXC domain swap-expressing bone marrow 
cells correlated with the colony assay and leukemia assay results.  Cells transduced with 
retroviruses encoding MSCVneo, MLL(CGBP CXXC)-AF9, MLL(MBD1 CXXC)-AF9 
and MLL(MBD1 MBD)-AF9 all expressed low levels of Hoxa9, while MLL(MLL 
CXXC)-AF9 and MLL(DNMT1 CXXC)-AF9 transduced cells showed overexpression of 
Hoxa9 as expected.  I next asked whether the non-transforming domain swap proteins 
would be able to localize to Hoxa9.  In the point mutant studies, I saw that MLL-AF9 
localizes to Hoxa9 regardless of whether or not the MLL CXXC domain can bind to 
DNA.  However, because the domain swap fusion proteins have many amino acid 
differences with MLL and may be involved in different protein-protein interactions, I was 
unsure if they would still be able to bind to the Hoxa9 locus.  The results of the chromatin 
immunoprecipitation assays, performed in bone marrow cells from the colony assays, 
showed that all of the domain swap MLL-AF9 proteins could localize to Hoxa9 
regardless of which CXXC or MBD domain was present.  Surprisingly, the MLL(MBD1 
CXXC)-AF9 and MLL(MBD1 MBD)-AF9 proteins showed an increased presence on 
Hoxa9 as compared to MLL-AF9 and the other domain swap proteins.  Overall these 
results again suggest that the CXXC domain of MLL is not required for the targeting of 
MLL to its target genes.  Rather the MLL CXXC domain is more important for binding 
to unmethylated DNA and possibly recruiting co-factors necessary for gene activation. 
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 To explain why the MLL(MBD1 CXXC)-AF9 and MLL(MBD1 MBD)-AF9 
proteins bind so strongly to Hoxa9, I hypothesized that the MBD1 MBD and CXXC 
domains, in the context of MLL-AF9, are able to recruit co-repressor proteins that 
produce a dominant effect to silence the locus.  It has been previously shown that the 
MBD1 MBD domain binds to co-repressor proteins HP1 and Suv39h1, a histone H3K9 
methyltransferase that also recruits repressive histone deacetylase enzymes.  This 
recruitment would act to further enforce transcriptional repression of gene targets such as 
Hoxa9 by promoting histone H3K9 methylation and histone deacetylation.114  With 
regard to the MBD1 CXXC domain swap construct, a region of MBD1 that includes the 
MBD domain and its first two CXXC domains was previously shown to be able to bind 
the chromatin assembly factor-1 (CAF1) and the histone methyltransferase SETDB1 
which trimethylates histone H3K9 on newly replicated, methylated DNA.113  These 
studies suggest that both the MBD and CXXC domains of MBD1 are able to recruit co-
repressor proteins to target genes, and may also be able to do so in the context of MLL-
AF9 when it localizes to Hoxa9.  It is also possible that it appears that, as compared to 
MLL-AF9, an increased number of the MLL(MBD1 CXXC)-AF9 and MLL(MBD1 
MBD)-AF9 proteins bind to Hoxa9 because the presence of these proteins causes the 
formation of heterochromatin with an increased number of nucleosomes and H3 histone 
proteins present at Hoxa9.  A chromatin immunoprecipitation experiment using an anti-
H3 antibody would need to be performed to confirm this hypothesis. 
 The repression domain of MLL, which is retained in MLL fusion proteins and 
includes the CXXC domain, has been shown to interact with multiple proteins.  The 
repression domain includes amino acids 1101-1400 of MLL, and has been further split 
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into RD1 (amino acids 1101-1250), which includes the CXXC domain (amino acids 
1149-1201), and RD2 (amino acids 1251-1400).  Our laboratory previously found that 
multiple repressor proteins bind to the MLL repression domain including the histone 
deacetylases HDAC1/2, C-terminal Binding Protein CtBP, and the Polycomb group 
proteins BMI-1 and HPC2.32  Full length MLL is primarily thought of as an activator of 
transcription, but the repression domain of MLL can also act to repress transcription of 
target genes.23  It is possible that the decision for MLL to act as an activator or repressor 
of transcription depends on which other proteins are recruited to MLL at target genes.  
So, when proteins such as HDAC, CtBP, and the Polycomb proteins bind to full length 
MLL, they may facilitate the repressive state of MLL function.  In addition, the 
cyclophilin protein Cyp33 binds to the third PHD finger of MLL and its presence 
promotes repression of MLL target genes HOXC8 and HOXC9.38  Cyp33 also enhances 
HDAC1 binding to the MLL repression domain,32 an effect that would be lost in MLL 
fusion proteins which do not retain the MLL PHD fingers.  HDAC1/2 and BMI-1 bind to 
both the RD1 and RD2 of MLL, while HPC2 binds to the RD1 region.  However, the 
minimal interaction domains within the MLL repression domain for binding to these 
repressor proteins has not been resolved.  It remains to be determined if the CXXC 
domain of MLL contributes to binding and if these repressor proteins bind to MLL fusion 
proteins, or if they can only be recruited to a full length MLL protein.   
 A series of domain swaps between MLL and MLL family member MLL2, which 
is not involved in chromosome translocations that cause leukemia, was performed in the 
context of an MLL-ENL fusion to test for the minimal region of MLL needed for bone 
marrow cells to transform in colony assays in vitro.125  The results indicate that the MLL 
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CXXC domain and a post-CXXC region (through MLL amino acid 1337) are both 
critical to colony formation.125  This suggests that the repression domain of MLL outside 
of the CXXC domain also plays an essential role in MLL leukemia.     
 Two recent studies have shown that the MLL repression domain mediates binding 
of MLL fusion proteins to the activating polymerase associated factor or PAF complex.33, 
34  The PAF complex (PAFc) promotes transcriptional elongation by recruiting ubiquitin 
ligases which ubiquitinate histone H2BK120,126 a mark which then promotes histone 
H3K4 and H3K79 methylation.127, 128  The study by Muntean et al isolated the minimal 
regions of MLL required for PAF1 (a component of PAFc) binding to regions flanking 
the MLL CXXC domain.33  They found that MLL amino acids 1115-1154, immediately 
upstream of the CXXC domain, and a region in RD2 that includes amino acids 1200 
through 1400, both bind to PAF1.  They also determined that the minimal region of MLL 
needed to transform bone marrow cells in vitro in colony assays includes MLL amino 
acids 1115-1299 fused to AF9.  Since this minimal region includes the regions that bind 
to PAF1, they concluded that MLL fusion proteins must bind to PAF1 in order to 
function.  In another study, Milne et al found that PAF1 binds to MLL amino acids 1100-
1250, the RD1 region, but not to MLL RD2.  They also tested the ability of PAF1 to bind 
to a region of CGBP that includes its CXXC domain and corresponds in length to the full 
MLL repression domain, and did not see any interaction.34  Arginine1153, which is 
located two amino acids before the first zinc-coordinating cysteine in the MLL CXXC 
domain, was determined to be an important amino acid in the interaction between MLL 
and PAFc, as binding decreased in the presence of an R1153A mutation.34  Interestingly, 
MLL arginine1153 is conserved in both the CGBP and DNMT1 CXXC domains.  As 
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CGBP CXXC does not function in the context of MLL-AF9, and PAF1 did not bind to a 
protein fragment containing the CGBP CXXC domain, we can conclude that the presence 
of arginine1153 is not sufficient for CXXC domains to function in the context of an MLL 
fusion protein.   
 It is possible that PAFc binding is one factor which may contribute to functional 
specificity of the either the larger repression domain region or the CXXC domain to MLL 
fusion function.  It is unknown if DNMT1 can interact with PAFc, but if MLL(DNMT1 
CXXC)-AF9 retains PAFc binding but MLL(CGBP CXXC)-AF9 does not, it could 
explain the difference in transformation potential between the two domain swap proteins.  
However, additional work is needed to reconcile the differences between the two papers 
that discovered the MLL-PAFc interaction and to definitively determine the regions of 
MLL that are required for PAFc binding.  As neither study isolated the 50 amino acid 
MLL CXXC domain as responsible for binding to PAF1, it seems that the larger 
repression domain, perhaps including regions in both RD1 and RD2, is responsible for 
recruiting the PAF complex.  If the CXXC domain is not involved in binding to PAF1, 
then it would be expected that both MLL(DNMT1 CXXC)-AF9 and MLL(CGBP 
CXXC)-AF9 would retain PAFc binding.   
 Other possible explanations as to why MLL(DNMT1 CXXC)-AF9 can transform 
bone marrow cells, but MLL(CGBP CXXC)-AF9 and MLL(MBD1 CXXC)-AF9 do not, 
could include recruitment of other as yet unidentified proteins which bind to both MLL 
and DNMT1 CXXC domains but are not recruited by CGBP CXXC or MBD1 CXXC.  
CGBP and MBD1 CXXC domains may also bind to factors inhibitory to MLL-AF9 
function.  Amino acid differences between the tested CXXC domains are highlighted in 
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Figure 20.  Residues shaded in red are identical between MLL and DNMT1 but not the 
other CXXC domains, suggesting they may be essential to MLL CXXC function.  
Residues depicted in green are identical between CGBP and MBD1 CXXC domains, but 
are not present in MLL or DNMT1, which suggests that the amino acids at these 
positions in CGBP or MBD1 may be inhibitory to CXXC function in MLL-AF9.  The red 
arginine1154 and lysine1186 appear on the DNA binding face of the CXXC domain, and 
as previously discussed, contribute to MLL CXXC DNA binding.  The red proline1164 
and asparagine1196, and green glutamine1157 and glycine1160 appear on the outer face 
of the domain.  These amino acids on the outer surface of the CXXC domain may affect 
other functions, including protein-protein interactions.  As proline1164 and 
asparagine1196 are common between the MLL and DNMT1 CXXC domains, they may 
be critical to the recruitment of an essential co-activator, while glutamine1157 and 
glycine1160 which appear in CGBP CXXC and MBD1 CXXC may inhibit this 
interaction.   
 MLL CXXC Cysteine1188, the non-structural, nonconserved cysteine which was 
discussed in a previous section, is located in close proximity to the CpG when the domain 
is bound to DNA (amino acid shaded in blue, see Figure 20B).  John Bushweller’s 
laboratory showed by NMR that mutation of cysteine1188 to aspartate causes loss of 
DNA binding of the isolated CXXC domain.  I confirmed that this C1188D mutation 
causes loss of function of MLL-AF9, likely due to introduction of a repulsive charge 
from the aspartate that repels DNA from the CXXC domain.  However, mutation of 
cysteine1188 to alanine was inert in that it did not decrease DNA binding of the MLL 
CXXC domain or reduce transformation of MLL-AF9.10  Interestingly, the DNMT1 
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CXXC has an alanine at this 1188 position, which may contribute to the ability of 
DNMT1 CXXC to function in MLL-AF9.   
 The DNMT1 and MLL CXXC domains share an ability to bind to unmethylated 
CpG DNA and can function with similar effects in the oncogenic MLL-AF9 fusion 
protein, but the two domains come from proteins that have very different functions.  MLL 
principally acts to maintain active transcription of target genes and through its SET 
domain trimethylates histone H3K4 as a mark and possible promoter of active 
transcription.  My dissertation work suggests that the main function of the MLL CXXC 
domain is to interact with unmethylated CpG DNA in the promoters of target genes and 
protect the target CpG residues from becoming DNA methylated, helping to promote an 
active transcriptional state of the target gene locus.  The DNMT1 DNA methyltransferase 
protein functions to maintain genomic DNA methylation patterns by propagating this 
transcriptionally repressive mark through DNA replication and cell division.  It was 
originally thought that the DNMT1 CXXC domain could recognize and bind to 
hemimethylated DNA, which is the target of DNMT1 enzymatic activity.109  Structural 
data has now indicated that the DNMT1 CXXC domain binds only to unmethylated CpG 
DNA.96  It has been hypothesized that the DNMT1 CXXC domain functions to recognize 
and bind to unmethylated CpGs that are encountered by DNMT1 following DNA 
replication, and to protect or sequester these CpGs from the enzymatic activity of the 
DNMT1 catalytic domain.96  This autoinhibitory role of the DNMT1 CXXC domain 
ensures that only newly replicated DNA that is hemimethylated could be targeted by the 
DNMT1 enzymatic activity.  Therefore, both the MLL and DNMT1 CXXC domain share 
a similar function to protect unmethylated CpG DNA from DNA methylation, but by 
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different mechanisms.  The MLL CXXC domain functions to prevent unmethylated 
target CpGs from becoming methylated by de novo DNA methyltransferase enzymes, 
while the DNMT1 CXXC domain prevents unmethylated CpGs from becoming 
methylated by the DNMT1 protein itself.   
 In summary, the CXXC domain of MLL contributes essential functions to MLL 
fusion proteins.  In this work, I showed that the CXXC domain of MLL is not absolutely 
required for the localization of MLL fusion proteins to gene targets, as was once 
hypothesized.  It is likely that full length MLL proteins also do not require the CXXC 
domain for target localization.  The DNA binding function of the MLL CXXC domain 
remains critical to MLL fusion proteins, however.  Point mutations that cause loss of 
MLL CXXC DNA binding cause MLL fusion proteins to lose their ability to cause 
overexpression of target gene Hoxa9 and to protect target CpG motifs in the Hoxa9 locus 
from becoming DNA methylated, and therefore are unable to promote transformation of 
bone marrow cells in vitro or cause leukemia in mice in vivo.  CXXC domain swap 
experiments furthered our understanding of the MLL CXXC domain.  I showed that 
CXXC binding to unmethylated CpG DNA is not the only critical function of the MLL 
CXXC domain, as the CGBP CXXC domain which retains this binding function is unable 
to function in an MLL fusion protein.  The DNMT1 CXXC domain, while possessing a 
much lower binding affinity for an unmethylated DNA target compared to the MLL 
CXXC domain, was still able to functionally replace the MLL CXXC domain in MLL-
AF9.  This suggests that the MLL CXXC domain is not unique in its ability to function in 
an MLL fusion protein, and that it must share some essential characteristics with the 
DNMT1 CXXC domain.  These shared functions may include the ability to bind to the 
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same set of proteins which are necessary for MLL fusion proteins to promote 
leukemogenesis.  By examining the amino acid sequences of the CXXC domains, in 
collaboration with Noah Birch, a biochemistry student in the laboratory, I identified 
several differences and similarities between the domains which may contribute to their 
functions.     
 The results of this project suggest several avenues for future experiments to 
explore.  It remains to be determined what functional characteristics are shared by the 
MLL and DNMT1 CXXC domains that are not present in the CGBP CXXC domain.  If 
minimal protein-protein interaction domains within the MLL repression domain to other 
proteins known to bind in this region, such as PAF1, could be carefully mapped, then the 
CXXC domain’s contribution to protein binding could be determined.  Additionally it 
would be interesting to use the MLL CXXC domain as bait in a yeast two-hybrid screen 
or other screening process to determine if any other as yet unidentified proteins interact 
directly with the MLL CXXC domain.  If certain proteins are identified that interact with 
the minimal MLL CXXC domain, then the other isolated CXXC domains could also be 
tested to see if they retain this binding ability as well.  In addition, the CXXC domain 
swap MLL-AF9 fusion proteins could also be tested for these interactions to determine if 
specific proteins bind in this context.  Another area currently under investigation by 
another member of our laboratory is the determination of the role of the redox state of 
cysteine1188 to MLL fusion protein function.  Finally, as the CXXC domain remains an 
essential feature to MLL fusion proteins, I hope that small molecule inhibitors directed 
toward the CXXC domain could lead to an effective targeted therapy for MLL leukemia 
patients.  The search for a CXXC domain inhibitor molecule is currently underway. 
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APPENDIX A: 
 
CLONING STRATEGY FOR CREATING AN MLL CONSTRUCT WITH ALTERED  
 
RESTRICTION ENZYME SITES TO BE USED FOR 
 
SWAPPING CXXC DOMAINS INTO MSCV-MLL-AF9 
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5’ MLL in pMCS5 
    EcoRI 
Start of MLL 
 
AatII  
aa 1150 
BamHI 
aa 1250 
SalI  
aa 1362 
CXXC domain 
No site 
aa 1201 
 
 
 
Digest MLL with BamHI –  
 
EcoRI AatII  No site BamHI overhangs SalI  
 aa 1150 aa 1201   aa 1250 aa 1362 
CXXC domain  
 
 
 
PCR amplify aa1201-1250, adding restriction sites to PCR products with primers 
    EcoRI 
Start of MLL 
 
AatII  
aa 1150 
BamHI 
aap 1250 
SalI  
aa 1362 
CXXC domain 
No site 
aa 1201 
 
 
 
 
 
 
Digest PCR products with BamHI and BglII 
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BamHI overhangs 
  aa 1250 
 
 
 
 
PCR amplify CXXC Domain: 
 
 
 
 
Digest PCR products with AatII and BamHI 
 
 
SalI  
aa 1362 
EcoRI 
 
AatII  
aa 1150 
CXXC domain 
No site 
aa 1201 
Ligate PCR products into the plasmid digested with BamHI: 1201 
BamHI  
overhang 
1250 BglII 
overhang 
BamHI site 
1201 
EcoRI 
 
AatII  
aa 1150 
CXXC domain 
No site 
aa 1201 
SalI  
aa 1362 1250 aa 1250 
 
Extra 50 bp 
of DNA!!! 
½ BamHI 
½ BglII site 
    EcoRI 
Start of MLL 
 
AatII  
aa 1150 
BamHI 
aa 1250 
SalI  
aa 1362 
CXXC domain 
No site 
aa 1201 
AatII 
1150 
BamHI 
1201 
AatII 
1150 
BamHI 
1201 
CXXC CXXC 
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Take ligation construct with extra DNA: 
BamHI site 
 
 
 
 
 
 
Final product 5’ MLL with BamHI site moved in pMCS5: 
 
 
 
 
 
 
EcoRI 
 
AatII  
aa 1150 
CXXC domain 
No site 
aa 1201 
SalI  
aa 1362 
aa 1201 
Extra 150 bp 
of DNA 
aa 1250 
½ BamHI 
½ BglII site 
aa 1250 
Digest with AatII and BamHI 
EcoRI 
½ BamHI 
½ BglII site SalI BamHI 1201 
 overhang 
AatII 
aa 1250 overhang aa 1362 
BamHI AatII 
1250/1201201 aa Ligate with new 
PCR products AatII BamHI 
1150 1201 
Deleted CXXC 
    EcoRI 
Start of MLL 
 
AatII  
aa 1150 
No site 
aa 1250 
SalI  
aa 1362 
CXXC domain 
BamHI 
aa 1201 
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